US20070190559A1 - Isolation of nucleic acid - Google Patents

Isolation of nucleic acid Download PDF

Info

Publication number
US20070190559A1
US20070190559A1 US11/671,426 US67142607A US2007190559A1 US 20070190559 A1 US20070190559 A1 US 20070190559A1 US 67142607 A US67142607 A US 67142607A US 2007190559 A1 US2007190559 A1 US 2007190559A1
Authority
US
United States
Prior art keywords
dna
sample
cells
genomic dna
detergent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/671,426
Inventor
Arne Deggerdal
Frank Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies AS
Original Assignee
Invitrogen Dynal AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10765877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070190559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Invitrogen Dynal AS filed Critical Invitrogen Dynal AS
Priority to US11/671,426 priority Critical patent/US20070190559A1/en
Publication of US20070190559A1 publication Critical patent/US20070190559A1/en
Priority to US12/054,332 priority patent/US7989614B2/en
Priority to US12/130,959 priority patent/US20090149646A1/en
Priority to US12/130,926 priority patent/US20090068724A1/en
Priority to US13/160,428 priority patent/US8691969B2/en
Assigned to INVITROGEN DYNAL AS reassignment INVITROGEN DYNAL AS CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: DYNAL BIOTECH AS, DYNAL BIOTECH ASA, DYNAL ASA, DNYAL AS
Priority to US14/183,999 priority patent/US20140291576A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/1013Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads

Definitions

  • the present invention relates to the isolation of nucleic acid, and especially to the isolation of DNA or RNA from cells.
  • the isolation of DNA or RNA is an important step in many biochemical and diagnostic procedures. For example, the separation of nucleic acids from the complex mixtures in which they are often found is frequently necessary before other studies and procedures e.g. detection, cloning, sequencing, amplification, hybridisation, cDNA synthesis etc. can be undertaken; the presence of large amounts of cellular or other contaminating material eg. proteins or carbohydrates, in such complex mixtures often impedes many of the reactions and techniques used in molecular biology. In addition, DNA may contaminate RNA preparations and vice versa. Thus, methods for the isolation of nucleic acids from complex mixtures such as cells, tissues etc. are demanded, not only from the preparative point of view, but also in the many methods in use today which rely on the identification of DNA or RNA eg. diagnosis of microbial infections, forensic science, tissue and blood typing, detection of genetic variations etc.
  • RNA identifications it is important for a conclusive diagnosis to be certain that the detected sequence is derived from an RNA molecule and not from genomic DNA contamination in the sample. For this reason, methods for the separation of RNA from DNA are important. Also, for RNA isolation rapid methods are required since RNA molecules usually are very unstable and rapidly degraded by RNases present in cells and body fluids. The quality of the RNA is probably the most important factor in determining the quality of the final results in protocols utilising mRNA, especially for cDNA synthesis. It is important to avoid DNA contamination of RNA preparations for a number of reasons. Firstly, DNA increases viscosity making sample handling difficult leading to poor RNA yield and also RNA of poor quality with the likelihood of DNA contamination. Also, DNA contamination may trap RNase enzymes and make downstream applications such as RT-PCR worthless.
  • RNA isolation involves lysis of the biological material by a detergent or chaotrope, possibly in the presence of protein degrading enzymes, followed by several extractions with organic solvents eg. phenol and/or chloroform, ethanol precipitation, centrifugations and dialysis of the nucleic acids.
  • organic solvents eg. phenol and/or chloroform
  • ethanol precipitation e.g. phenol and/or chloroform
  • centrifugations e.g. phenol and/or chloroform
  • dialysis of the nucleic acids e.g. phenol and/or chloroform
  • the purification of RNA from DNA may involve a selective precipitation with LiCl or a selective isolation with acidic guanidinium thiocyanate combined with phenol extractions and ethanol precipitation.
  • RNA purification strategies involve isolation of total RNA and fractionation of the isolated RNA. Preparation of high-quality mRNA is an important step in the analysis of gene structure and gene regulation.
  • mRNAs have a poly(A)tail, typically about 50 to 300 nucleotides long. Such mRNA is referred to as polyadenylated or poly(A) + mRNA.
  • polyadenylated or poly(A) + mRNA In separating this polyadenylated RNA from the non-adenylated RNA which accounts for 95% or more of a cell's total RNA, advantage is taken of this poly(A) tail and some type of affinity separation directed toward the poly(A) tail is performed.
  • the conventional technology has involved purification of total RNA as a first step and selection of poly(A) + RNA by affinity chromatography using oligo(dT)-cellulose as the second step. This strategy, is rather time-consuming and labour-intensive.
  • An alternative strategy for mRNA purification is to use oligo(dT) linked to solid supports such as microplates, latex, agarose or magnetic beads.
  • RNA purification which may be used in conjunction with the solid phase approach is to carry out the lysis of the biological material and the subsequent hybridisation to oligo dT in LiCl and LiDS/SDS buffers, thereby avoiding extra steps such as phenol extraction or proteinase-K digestion.
  • the whole direct mRNA isolation takes approximately 15 minutes and since the mRNA is stable for more than 30 minutes in the lysis buffer, this ensures the high quality of the mRNA purified.
  • a disadvantage of this method is that mRNA per weight unit of tissue is affected by the amount of tissue used and above a critical threshold of lysed cells, the yield of mRNA decreases.
  • GTC guanidinium isothiocyanate
  • sarkosyl guanidinium isothiocyanate
  • a GTC-buffer system is preferred by most researchers due to the ability of this chaotropic salt to inhibit RNases. This may also be used in combination with the magnetic bead approach.
  • the viscosity of cell lysates in 4M GTC is high and the beads are not effectively attracted by the magnet, resulting in an increased risk for DNA contamination, both for beads and other solid phases, and lower yields.
  • nucleic acid may be isolated from a sample in a form suitable for amplification or other downstream processes, by a simple and easy to perform procedure which involves treating the sample with detergent and allowing the nucleic acid to bind to a solid support, whereupon the nucleic acid may be readily separated from the sample, eg. by removal of the support.
  • the binding of the nucleic acid is independent of its sequence.
  • the present invention thus provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample.
  • the nucleic acid may be DNA, RNA or any naturally occurring or synthetic modification thereof, and combinations thereof.
  • the nucleic acid will be DNA, which may be genomic, or, cDNA, and single or double stranded or in any other form.
  • the method of the invention may conveniently be coupled with a further step to isolate RNA from the same sample.
  • RNA separations will be described in more detail below.
  • the samples may be any material containing nucleic acid, including for example foods and allied products, clinical and environmental samples.
  • the sample will generally be a biological sample, which may contain any viral or cellular material, including all prokaryotic or eukaryotic cells, viruses, bacteriophages, mycoplasmas, protoplasts and organelles.
  • Such biological material may thus comprise all types of mammalian and non-mammalian animal cells, plant cells, algae including blue-green algae, fungi, bacteria, protozoa etc.
  • Representative samples thus include whole blood and blood-derived products such as plasma, serum and buffy coat, urine, feces, cerebrospinal fluid or any other body fluids, tissues, cell cultures, cell suspensions etc.
  • the sample may also include relatively pure starting materials such as a PCR product, or semi-pure preparations obtained by other nucleic acid recovery processes.
  • the nucleic acid-containing sample may, generally speaking, simply be contacted with the detergent, and a solid phase which may be added to the sample prior to, simultaneously with, or subsequently to the detergent. If necessary, this may be preceded by one or more separate steps to disrupt structural components such as cell walls or to achieve lysis. Procedures for achieving this are well known in the art. Thus, for example, although some cells eg. blood cells, may be lysed by the detergent alone, other cells, eg. plant or fungal cells or solid animal tissues may require more vigorous treatment such as, for example, grinding in liquid nitrogen, heating in the presence of detergent, alkaline lysis in the presence of detergent.
  • lysis and melting of the paraffin
  • certain more compact tissues may require enzyme treatment, for example using proteinase K to obtain sufficient release of nucleic acid.
  • the various components are mixed and simply allowed to stand for a suitable interval of time to allow the nucleic acid to bind to the support.
  • agents such as enzymes eg. proteinase K are being used, they may be included in with the detergent.
  • the support is then removed from the solution by any convenient means, which will depend of course on the nature of the support, and includes all forms of withdrawing the support away from the sample supernatant, or vice versa, for example centrifugation, decanting, pipetting etc.
  • the conditions during this process are not critical, and it has been found convenient, for example, simply to mix the sample with the detergent in the presence of a solid phase, and allow it to stand at room temperature, for 5 to 20 minutes, before separating.
  • the reaction time is not critical and as little as 5 minutes is often enough. However, if convenient, longer periods may be used, eg. 0.5 to 3 hours, or even overnight.
  • Mixing can be done by any convenient means, including for example simple agitation by stirring or vortexing. Also, if desired, higher or lower temperatures may be used, but are not necessary.
  • the detergent may be any detergent, and a vast range are known and described in the literature.
  • the detergent may be ionic, including anionic and cationic, non-ionic or zwitterionic.
  • the term “ionic detergent” as used herein includes any detergent which is partly or wholly in ionic form when dissolved in water. Anionic detergents have been shown to work particularly well and are preferred. Suitable anionic detergents include for example sodium dodecyl sulphate (SDS) or other alkali metal alkylsulphate salts or similar detergents, sarkosyl, or combinations thereof.
  • SDS sodium dodecyl sulphate
  • other alkali metal alkylsulphate salts or similar detergents, sarkosyl, or combinations thereof.
  • the detergent may be used in a concentration of 0.2 to 30% (w/v), eg. 0.5 to 30%, preferably 0.5 to 15%, more preferably 1 to 10%.
  • concentrations of 1.0 to 5% eg. 0.5 to 5% have been shown to work well.
  • the detergent may be supplied in simple aqueous solution, which may be alkaline or acidic, or more preferably in a buffer.
  • Any suitable buffer may be used, including for example Tris, Bicine, Tricine, and phosphate buffers.
  • a source of monovalent cations eg. a salt
  • Suitable salts include chloride salts, e.g. sodium chloride, lithium chloride etc. at concentrations of 0.1 to 1M, eg. 250 to 500 mM.
  • other components such as enzymes, may also be included.
  • chelating agents eg. EDTA, EGTA and other polyamino carboxylic acids conveniently at concentrations of 1 to 50 mM etc.
  • reducing agents such as dithiotreitol (DTT) or ⁇ -mercaptoethanol, at concentrations of for example 1 to 10 mM.
  • Preferred detergent compositions may for example comprise:
  • the detergent functions in the method to lyse the nucleic acid containing material, eg. the cells and nuclei to release the nucleic acid.
  • the detergent is also believed to help to disrupt the binding of proteins, eg. DNA-binding proteins, to the nucleic acid and to reduce the problem of contaminants in the sample sticking to the solid support.
  • the solid support may be any of the well known supports or matrices which are currently widely used or proposed for immobilisation, separation etc. These may take the form of particles, sheets, gels, filters, membranes, fibers, capillaries, or microtitre strips, tubes, plates or wells etc.
  • the support may be made of glass, silica, latex or a polymeric material. Preferred are materials presenting a high surface area for binding of the nucleic acid. Although not wishing to be bound by theoretical considerations, it is believed that the nucleic acid binding process may be assisted by the nucleic acid “wrapping around” the support.
  • Such supports will generally have an irregular surface and may be for example be porous or particulate eg. particles, fibres, webs, sinters or sieves. Particulate materials eg. beads are generally preferred due to their greater binding capacity, particularly polymeric beads.
  • a particulate solid support used according to the invention will comprise spherical beads.
  • the size of the beads is not critical, but they may for example be of the order of diameter of at least 1 and preferably at least 2 ⁇ m, and have a maximum diameter of preferably not more than 10 and more preferably not more than 6 ⁇ m. For example, beads of diameter 2.8 ⁇ m and 4.5 ⁇ m have been shown to work well.
  • Monodisperse particles that is those which are substantially uniform in size (eg. size having a diameter standard deviation of less than 5%) have the advantage that they provide very uniform reproducibility of reaction.
  • Monodisperse polymer particles produced by the technique described in U.S. Pat. No. 4,336,173 are especially suitable.
  • Non-magnetic polymer beads suitable for use in the method of the invention are available from Dyno Particles AS (Lillestrom, Norway) as well as from Qiagen, Pharmacia and Serotec.
  • magnetic beads are preferred.
  • the term “magnetic” as used herein means that the support is capable of having a magnetic moment imparted to it when placed in a magnetic field, and thus is displaceable under the action of that field.
  • a support comprising magnetic particles may readily be removed by magnetic aggregation, which provides a quick, simple and efficient way of separating the particles following the nucleic acid binding step, and is a far less rigorous method than traditional techniques such as centrifugation which generate shear forces which may degrade nucleic acids.
  • the magnetic particles with nucleic acid attached may be removed onto a suitable surface by application of a magnetic field eg. using a permanent magnet. It is usually sufficient to apply a magnet to the side of the vessel containing the sample mixture to aggregate the particles to the wall of the vessel and to pour away the remainder of the sample.
  • superparamagnetic particles for example those described by Sintef in EP-A-106873, as magnetic aggregation and clumping of the particles during reaction can be avoided, thus ensuring uniform and nucleic acid extraction.
  • the well-known magnetic particles sold by Dynal AS (Oslo, Norway) as DYNABEADS, are particularly suited to use in the present invention.
  • Functionalised coated particles for use in the present invention may be prepared by modification of the beads according to U.S. Pat. Nos. 4,336,173, 4,459,378 and 4,654,267.
  • beads, or other supports may be prepared having different types of functionalised surface, for example positively charged or hydrophobic. Weakly and strongly positively charged surfaces, weakly negatively charged neutral surfaces and hydrophobic surfaces eg. polyurethane-coated have been shown to work well.
  • solid supports which have been modified to permit the selective capture of desired cells, viruses etc. containing the nucleic acid.
  • supports carrying antibodies, or other binding proteins, specific for a desired cell type may be used. This may introduce a degree of selectivity to the isolation of the nucleic acid, since only nucleic acid from a desired target source within a complex mixture may be separated.
  • a support may be used to separate and remove the desired cell type etc. from the sample, following which, the detergent is added to achieve lysis, release of the nucleic acid, and binding to the support.
  • the support may be provided with binding partners to assist in the selective capture of nucleic acids.
  • binding partners for example, complementary DNA or RNA sequences, or DNA binding proteins may be used, or viral proteins binding to viral nucleic acid.
  • the attachment of such proteins to the solid support may be achieved using techniques well known in the art.
  • washing buffers or other media may be used. Generally speaking, low to moderate ionic strength buffers are preferred eg. 10 mM Tris-HCl at pH 8.0/10 mM NaCl. Other standard washing media, eg. containing alcohols, may also be used, if desired.
  • the support carrying the nucleic acid may be transferred eg. resuspended or immersed into any suitable medium eg. water or low ionic strength buffer. Depending on the support and the nature of any subsequent processing desired, it may or may not be desirable to release the nucleic acid from the support.
  • a particulate solid support such as magnetic or non-magnetic beads
  • this may in many cases be used directly, for example in PCR or other amplifications, without eluting the nucleic acid from the support.
  • elution is not necessary since although the DNA may be randomly in contact with the bead surface and bound at a number of points by hydrogen bonding or ionic or other forces, there will generally be sufficient lengths of DNA available for hybridisation to oligonucleotides and for amplification.
  • elution of the nucleic acid may readily be achieved using known means, for example by heating, eg. to 65° C. for 5 to 10 minutes, and following which the support may be removed from the medium leaving the nucleic acid in solution. Such heating is automatically obtained in PCR by the DNA denaturation step preceding the cycling program.
  • RNA from DNA may be removed by destroying the RNA before the DNA separation step, for example by addition of an RNase or an alkali such as NaOH.
  • the method of the invention may be used to separate sequentially DNA and RNA from the sample. It may also be used to remove DNA from a sample in an RNA purification procedure.
  • the sequential separation may take place using two different solid phases, for example solid supports which can differentiate between DNA and RNA.
  • a method may comprise carrying out a first step separation to isolate DNA as described above.
  • a further solid support can then be added to the sample to capture the RNA remaining in the sample, either by using a solid support that can bind the RNA or any remaining nucleic acid, or a solid support that can capture specific RNA molecules (eg. by carrying a complementary nucleic acid probe), or a subset of RNA molecules eg. polyadenylated RNA.
  • RNA molecules eg. polyadenylated RNA.
  • DNA isolation procedure of the invention may also readily be combined, as a preliminary step, with other conventional RNA purification procedures, for example DNA isolation with detergent according to invention may be carried out before a selective RNA precipitation step, for example using LiCl or before RNA separation using GTC and sarkosyl.
  • the sample is lysed in the presence of detergent and the DNA is allowed to bind to a solid support, whereupon the DNA may readily be separated from the sample by removal of the support. If desired, the DNA can rapidly and easily be further handled for amplification or other downstream processes.
  • the RNA may then be isolated. This can be by a solid phase based system as described above, including a repetition of the method of the invention, or by conventional techniques such as extractions, precipitations or affinity chromatography.
  • a particularly advantageous embodiment of the invention is to use the isolation method of the invention to remove DNA from a sample prior to isolation of RNA, such that the viscosity of the lysed sample is reduced and a specific isolation of RNA molecules is favored which again reduces or avoids the possibility for DNA contamination of the RNA.
  • Such a method also has the advantage of being quick to perform.
  • the invention is advantageously amenable to automation, particularly if particles, and especially, magnetic particles are used as the support.
  • kits represent a further aspect of the invention.
  • this aspect of the invention provides a kit for isolating nucleic acid from a sample comprising a solid support and one or more detergents.
  • kits may be buffers, salts, lysis agents eg. proteinases, chelating agents and reducing agents.
  • lysis agents eg. proteinases, chelating agents and reducing agents.
  • kits may further comprise means for isolating RNA eg. a second solid support for isolating RNA, for example a support provided with probes for capture of RNA eg. oligo dT or probes of complementary sequence to the desired target, or a chaotrope or selective precipitating agent.
  • a second solid support for isolating RNA for example a support provided with probes for capture of RNA eg. oligo dT or probes of complementary sequence to the desired target, or a chaotrope or selective precipitating agent.
  • FIG. 1 shows as optical density scan of DNA isolated as described in Example 1 (ordinate shows absorbance (OD), abscissa shows wavelength (nM)). Maximum absorbance (0.427) at 257.6 nM; minimum absorbance (0.292) at 236.4 nM; at a threshold of 0.100;
  • FIG. 2 shows gel electrophoresis of a sample of DNA isolated as described in Example 1 (lane 1: isolation; lane 2: .lamda. Hind III (molecular weight marker));
  • FIG. 3 shows agarose gel electrophoresis of the PCR product of Example 2 (lane 1: PCR product; lane 2: .lamda. Hind III; lane 3: negative PCR control); and
  • FIG. 4 shows agarose gel electrophoresis of the PCR product of Example 5 (lane 1: .lamda. Hind III; lanes 2 and 3: isolations A and B respectively; lanes 4 and 5: negative control; lane 6: .lamda. Hind III).
  • FIG. 5 show the comparison between traditionally isolated DNA and DNA isolated with Dynabeads DNA DIRECT.
  • Panel I shows the amount of genomic DNA isolated from 10 ⁇ l of whole blood with Dynabeads DNA DIRECT including the optional elution step (lanes 1 and 2), with Dynabeads DNA DIRECT with the elution step omitted (lanes 3 and 4), and with traditional DNA isolation (lanes 5 and 6).
  • the molecular weight marker in lane 7 is .lamda. HindIII.
  • Panel II shows the integrity of DNA isolated by Dynabeads DNA DIRECT.
  • Lanes 1 and 2 show AMXY PCR from 20 ng of DNA isolated with Dynabeads DNA DIRECT from a male and female donor respectively.
  • Lanes 4 and 5 show AMXY PCR from 200 ng DNA isolated by traditional methods from a female and a male donor respectively.
  • Lane 3 is the negative control.
  • FIG. 6 shows the reproducibility of Dynabeads DNA DIRECT.
  • the figure shows five independent Dynabeads DNA DIRECT isolations from each of two donors. Half of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
  • Molecular weight markers are .lamda. HindIII (lanes marked M) or 100 bp ladder (lane marked L).
  • FIG. 7 shows the effect of different anticoagulants.
  • the figure shows Dynabeads DNA DIRECT isolations from whole blood that is not anticoagulated and from blood anticoagulated with EDTA, citrate, or S heparin. The two isolations from blood with the same anticoagulant were performed on blood from different donors (A or B). One quarter of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, except for heparin, where half the DNA obtained from 5 ⁇ l is shown. 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure, except for heparin, where 20% of the isolated DNA was used as starting material.
  • FIG. 8 shows the effect of sample storage conditions.
  • Panel I shows Dynabeads DNA DIRECT isolations from EDTA blood that has been used fresh, refrigerated for 4 days, or frozen for 4 days. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
  • Panel II shows Dynabeads DNA DIRECT isolations from citrate blood that has been used fresh or air dried and rehydrated. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
  • FIG. 9 shows Dynabeads DNA DIRECT from bone marrow and culture cells.
  • Panel I shows Dynabeads DNA DIRECT isolations from 1, 2 and 5 ⁇ l of bone marrow from each of two donors. A or B above the lanes denote the identity of the donor. Half of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
  • Panel II shows two Dynabeads DNA DIRECT isolations from 4 ⁇ 10 5 Daudi cells. One tenth of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 1 ⁇ l of a total of 120 ⁇ l isolated DNA is shown in the lower part of the figure.
  • the molecular weight marker is .lamda. HindIII for the genomic DNA and 100 bp ladder for the PCR products.
  • FIG. 10 shows Dynabeads DNA DIRECT from formalin fixed, paraffin embedded material.
  • Lane A is 20% of the PCR product from a reaction started with DNA isolated by DNA DIRECT from a formalin fixed, paraffin embedded section of liver.
  • Lane M is molecular weight marker (100 bp ladder)
  • lane B is positive control (PCR from 20 ng human DNA)
  • lane C is negative control (PCR from water).
  • FIG. 11 shows Dynabeads DNA DIRECT for mRNA purification.
  • mRNA was isolated from 1 million Daudi cells per sample with Dynabeads Oligo(dT) 25 after removal of DNA with Dynabeads DNA DIRECT.
  • Increasing amounts of DNA DIRECT Dynabeads were used to remove genomic DNA; 1 mg in lane 1 and 2; 2 mg in lane 3 and 4; 5 mg in lane 5 and 6 and 10 mg in lane 7 and 8.
  • Lane 9 and 10 are controls where no DNA was removed before direct mRNA purification.
  • the extra bands on the top of the picture show contaminating genomic DNA in lane 9 and 10.
  • the two strong bands in all lanes represent ribosomal RNA.
  • FIG. 12 shows the results of DNA isolation and PCR amplification from (A) bacteria, (B) fungi, (C) algae and (D) plants.
  • DNA was isolated with 200 ⁇ l DNA DIRECT (one sample test) and 20% of the isolated DNA and 10% of the PCR products were analysed by agarose electrophoresis.
  • DNA 2.5% of the isolated DNA was used per PCR reaction, for the other samples 5% was used.
  • 16S rRNA regions were amplified from bacterial genomic DNA and from algae chloroplast DNA. From fungi- and algae genomic DNA, 18S rDNA were amplified. Amplification of the group I intron chloroplast trnL and parts of the genomic B15C gene are shown for plants.
  • the negative controls are PCR on samples without DNA prepared in the same way as the other reactions.
  • the solid phase was then washed twice with 1 ml washing buffer [50 mM NaCl/10 mM TrisCl pH 8.0/1 mM EDTA]. Finally, the beads, with bound DNA, were resuspended in 0.1 ml water, and incubated for 5 minutes at 65° C. The beads were attracted to a magnet, and the liquid phase withdrawn. The liquid phase was then analyzed for its DNA content. Results from an optical density scan ( FIG. 1 ) are in accordance with pure DNA. The OD 260 /OD 280 ratio is 1.72; pure DNA in water or TE has a ratio of 1.7-1.9. With pure DNA, the concentration can be determined from the OD 260 of the solution.
  • Example 1 was repeated using the following combination of lysis buffers and washing buffers, and the following results were obtained: Lysis buffer Washing buffer Result 2% SDS 50 mM NaCl/1 ⁇ TE +++ 2% SDS/1 ⁇ TE 50 mM NaCl/1 ⁇ TE +++ 2% SDS/1 ⁇ TE/10 mM NaCl 50 mM NaCl/1 ⁇ TE +++ 5% SDS 50 mM NaCl/1 ⁇ TE +++ 5% SDS/1 ⁇ TE 50 mM NaCl/1 ⁇ TE +++ 5% SDS/1 ⁇ TE/10 mM NaCl 50 mM NaCl/1 ⁇ TE +++ 1% LiDS/10 ⁇ TE/0.5 M LiCl 50 mM NaCl/1 ⁇ TE +++ 1% LiDS/10 ⁇ TE/0.5 M LiCl 150 mM LiCl/1 ⁇ TE +++ 5% LiDS 150 mM LiCl/1 ⁇ TE +++ 5%
  • This experiment consisted of two identical isolations. 50 ⁇ l blood was mixed with 50 ⁇ l PBS [150 mM NaCl/10 mM NaH 2 PO 4 /Na 2 HPO 4 , pH 7.4] and 10 ⁇ l (4 ⁇ 10 6 beads) Dynabeads® M-450 Pan-T (CD2) (available from Dynal AS, Oslo, Norway). The mixture was then incubated for 30 minutes at room temperature with gentle tilting and rotation. The cell/beads complex was attracted to a magnet and the fluid withdrawn.
  • PBS 150 mM NaCl/10 mM NaH 2 PO 4 /Na 2 HPO 4 , pH 7.4
  • Dynabeads® M-450 Pan-T CD2
  • the cell/beads complex was then washed four times in 200 ⁇ l PBS, before 200 g Dynabeads® M-280* (as above) and 2001 lysis buffer [100 mM Tris-HCl, pH 8.0/500 mM LiCl/10 mM EDTA, pH 8.01/1% LiDS] was added. The mixture was incubated for 5 minutes at room temperature, before the DNA/beads complex was attracted to a magnet, and the supernatant withdrawn.
  • the DNA/beads complex washed twice with 200 ⁇ l washing buffer [10 mM Tris-Hcl, pH 8.0/150 mM LiCl/1 mM EDTA, pH 8.0] and resuspended in 50 ⁇ l water. After 5 minutes at 65° C., the beads were attracted to a magnet and the supernatant transferred to a new tube. 5 ⁇ l of the supernatant was used as template for polymerase chain reaction (GAPDH PCR as described in Example 7), which gave large amounts of product, as visualised on agarose gel electrophoresis ( FIG. 4 ).
  • GPDH PCR polymerase chain reaction
  • genomic DNA was isolated from 5 ml of EDTA anticoagulated blood.
  • Four isolations from 10 ⁇ l of the same blood sample were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway, containing beads equivalent to Dynabeads® M-280* as described in Example 1).
  • the DNA from two of the isolations was eluted for 5 minutes at 65° C., while the DNA from the other two isolations was left in the presence of the Dynabeads. All the DNA from the four Dynabeads DNA DIRECT isolations was loaded onto an agarose gel, as was 0.2% of traditionally isolated DNA. The fraction of the traditionally isolated DNA loaded corresponds to the yield from 10 ⁇ l of blood (0.2% of 5 ml).
  • Dynabeads DNA DIRECT lysis of the blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with 10 ⁇ l of blood in a 1.5 ml microcentrifuge tube (200 ⁇ g uncoated Dynabeads in Lysis/binding buffer). Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • MPC-E Dynamic's Magnetic Particle Collector E
  • the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 ⁇ l of TE pH 8.0 (provided in the kit).
  • the DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 ⁇ TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • DNA DIRECT was used to isolate DNA from ACD blood from two different donors, one male and one female. From each of the isolations, 10% was used as starting material for PCR amplification of an amplicon in the X-Y homologous amelogenin (AMXY) gene (Akane, A., K, Matsubara, H. Nakamura, S. Takahashi and K. Kimura. 1994. Purification of Highly Degraded DNA by Gel Filtration for PCR. BioTechniques 16 (2):235-238), as was 200 ng from each of two traditional DNA isolations.
  • AXY homologous amelogenin
  • PCR reactions were performed in a 50 ⁇ l reaction volume, 10 ⁇ PCR buffer (Perkin Elmer) was added to a final concentration of 1 ⁇ , dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers AMXY-1F (5′-CTGATGGTTGGCCTCAAGCCT-GTG-3′) and AMXY-4R (5′-TTCATTGTAAGAGCAAAGCAAACA-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the AMXY amplicon were 4 min at 94° C., 38 ⁇ [30 sec at 94° C., 30 sec at 55° C., 1 min at 72° C.], 10 min at 72° C.
  • Lysis/binding buffer 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA
  • sample A 3.6 ⁇ 10 6 cells/ml
  • sample B 2.6 ⁇ 10 6 cells/ml
  • Lysis of the blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • MPC-E Dynamic's Magnetic Particle Collector E
  • the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit). This resuspension was used for PCR and gel electrophoresis without any elution.
  • PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene was performed in a 50 ⁇ l reaction volume, 10 ⁇ PCR buffer (Perkin Elmer) was added to a final concentration of 1 ⁇ , dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers GAPDH-Forward (5′-ACAGTCCATGCCATCACTGCC-3′) and GAPDH-Reverse (5′-GCCTGCTTCACCACCCTTG-3′) were added per reaction.
  • GAPDH-Forward 5′-ACAGTCCATGCCATCACTGCC-3′
  • GAPDH-Reverse 5′-GCCTGCTTCACCACCCTTG-3′
  • PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94° C., 34 ⁇ [30 sec at 94° C., 30 sec at 61° C., 1 min at 72° C.], 10 min at 72° C.
  • Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from untreated whole blood as well as blood anticoagulated with EDTA, Citrate or Heparin. From each type of starting material, two separate isolations were performed, with blood from different donors.
  • the buffer components in the kit are as described in example 6.
  • Lysis of the DNA containing cells from blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with 5 ⁇ l Heparin blood or 10 ⁇ l of other blood samples in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • MPC-E Dynamic's Magnetic Particle Collector E
  • the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 20-40 ⁇ l of TE pH 8.0 (provided in the kit). We used 40 ⁇ l as the standard volume, but 20 ⁇ l if the starting material was Heparin blood.
  • PCR was performed directly on the suspension in TE, with the Dynabeads present. All PCR reactions were performed in a 50 ⁇ l reaction volume, 10 ⁇ PCR buffer (Perkin Elmer) was added to a final concentration of 1 ⁇ , dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction.
  • Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from EDTA blood from two different donors: What was remaining of the blood samples were then divided into two, one part that was stored at +4° C. and one that was stored at ⁇ 20° C. After 4 days, the frozen samples were thawed, and DNA was isolated from both the frozen samples and the samples that had been kept at +4° C.
  • the buffer components of the kit are as described in example 6.
  • Lysis of the blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • MPC-E Dynamic's Magnetic Particle Collector E
  • the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
  • heparinized bone marrow 1, 2, and 5 ⁇ l of heparinized bone marrow from each of two healthy donors were used as starting material for DNA isolation with DNA DIRECT.
  • the buffer components are as described in example 6. Lysis of the bone marrow was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with 1-5 ⁇ l of heparinized bone marrow in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E(MPC-E)), and the lysate was aspirated and discarded.
  • the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
  • DNA isolation from 4 ⁇ 10 5 cultured cells was performed as described above, except that 1 ml (five sample tests) of Dynabeads DNA DIRECT was used. Accordingly, the washing steps were performed in 1 ml washing buffer.
  • the DNA/Dynabeads complex was resuspended in 120 ⁇ l TE, and as for bone marrow, no elution step was performed after the resuspension.
  • Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from a formalin fixed, paraffin embedded section of liver.
  • the buffer components of the kit and the bead concentration are as described in example 6.
  • Lysis of the sample was obtained by adding 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT to the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads. The lysate, containing DNA and Dynabeads was transferred to a fresh tube, leaving cell debris and paraffin behind.
  • the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • MPC-E Dynamic's Magnetic Particle Collector E
  • the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 ⁇ l of sterile water. This suspension, with the Dynabeads present, was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8.
  • the PCR product was visualised on an ethidium bromide stained 1.5% agarose gel. 10 ⁇ l of the 50 ⁇ l reaction was loaded on the gel. Electrophoresis was performed in 1 ⁇ TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The result of this experiment is shown in FIG. 10 .
  • PCR amplifiable material has clearly been obtained from the formalin fixed, paraffin embedded section of liver.
  • mRNA was isolated from 1 million Daudi cells per sample. The cells were lysed in 0.75 ml Lysis/binding buffer with DNA DIRECT Dynabeads present in the buffer. The samples were incubated for 5 minutes and the DNA-Dynabead complexes were collected by applying a Dynal MPC-E magnet for 2 minutes. Different amounts of DNA DIRECT beads were used to remove genomic DNA; 1, 2, 5 and 10 mg per sample ( FIG. 11 ).
  • the lysate from each sample was transferred to new tubes with 1 mg Dynabeads Oligo(dT) 25 according to standard procedure (Dynals mRNA DIRECT kit protocol).
  • the Dynabeads were mixed with the lysate to capture the polyadenylated mRNA by hybridisation for 5 minutes at room temperature.
  • the mRNA-Dynabead complexes were collected with the MPC-E magnet by placing the tubes in the magnetic stand for 2 minutes. The solution was removed and discarded. Washing solution with LiDS (0.75 ml) was added and the beads were washed thoroughly by pipetting up and down.
  • the mRNA-Dynabead complexes were collected with the magnet, and the washing procedure was repeated once with washing buffer with LiDS and twice with washing buffer without detergent. Finally, the purified mRNA was eluted from the Dynabeads in 20 ⁇ l 5 mM Tris-HCl pH 7.5 buffer, by incubation at 65° C. for 2 minutes. The eluates were analysed by non-denaturing gel electrophoresis in a 1.0 t agarose gel with ethidium bromide. FIG. 11 shows the results from this experiment.
  • Lysis/binding buffer 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer with LiDS: 0.15 M LiCl 0.1% LiDS 10 mM Tris-HCl pH 8.0 1 mM EDTA Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA
  • E. coli and Baceillus cereus were grown overnight at 37° C. in LB medium, Agrobacterium tumefaciens was grown overnight in YEB medium for about 40 hours at 28° C. (Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbour Laboratory, NY.). Cyanobacteria and Prochlorthrix were grown in NIVA medium for 14 days at 18° C. using an illumination of 20 micro Einstein (Norwegian Institute of Water Research, 1991, Culture collection of algae). 20-200 million bacteria or 450,000 cyanobacteria were used per DNA isolation.
  • Agar plates containing 2% malt extract was used for mycelia growth and incubated for 14 days at room temperature. Mycelia was isolated by scraping the surface of the agar plates with a spatula. Fungi fruitbodies were obtained from natural populations. In the range of 1-3 mg air dried and 3-20 mg fresh fungi fruitbodies were used per DNA isolation.
  • Bakers yeast Saccharomyces cerevisiae was obtained from a commercial supplier. Algae were cultured under illumination in IMR-medium for 7 days (Eppley, R et al., 1967, Exp. Mar. Biol. Ecol. 1, 191-208). Fresh leaves from Arabidopsis thaliana and barley ( Hordeum vulgare ) were picked from young plants (3 weeks old). Epithelia were obtained from perch ( Perca fluvatilis ) fins. About 1 mg wet weight yeast, 30-100 mg young plant leaves and 100-400 mg perch were used per DNA isolation.
  • Multicellular tissues with rigid cell walls were mechanically broken to increase DNA yield.
  • Fungi fruitbodies were ground with forceps for about 2 minutes.
  • Plant leaves were homogenised for 2 minutes in liquid nitrogen with a pestle (Kontes Scientific Instruments, Vineland, N.J., USA). For all other samples no mechanical work was required for cell breakage.
  • DNA isolations were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway). Lysis of the cells and organisms were obtained by mixing 200 ⁇ l of Dynabeads DNA DIRECT (200 ⁇ g uncoated Dynabeads in Lysis/binding buffer) with the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 to 15 minutes to allow adsorption of genomic DNA to the Dynabeads. For some bacteria and for plants, incubation at 65° C. for 15 minutes was used to improve lysis before the adsorption step.
  • Dynabeads DNA DIRECT kit, commercially available from Dynal AS, Oslo, Norway.
  • the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • MPC-E Dynamic's Magnetic Particle Collector E
  • the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit) by vigorous pipetting. Elution was performed by heating the suspension to 65° C. for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the experiments.
  • Lysis/binding buffer 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mm EDTA
  • the amplicon was a 16S rRNA region corresponding to E. coli base 334 to 939 according to IUD numbering from bacteria and algae chloroplasts (Brosius, J., et al., 1978, Proc. Natl. Acad. Sci., USA, 57, 4801-4805).
  • Primer CC has a 5′ end complementary to ⁇ 21 M13 universal primer, making it suitable for direct DNA sequencing. Amplification: 30 cycles of 96° C. for 15 seconds and 70° C. for 2 minutes.
  • a 18S rRNA region (ca. 600 bp.) was amplified with the primers NS3 and NS4 as described by White et al., 1990. In “PCR Products, a Guide to Methods and Applications” by Innis, M. A. et al., page 315-322, Academic Press, New York.
  • tRNL group I intron in chloroplasts were amplified with the primers C and D described by Fangan et al., 1994, BioTechniques 16, 484-494.
  • a part of the Arabidopsis thaliana gene BI5C (800 bp) was amplified with the primers: 5′-CGGGATCCCTAGGAGACACGGCCG-3′ and 5′-GGAATTCGATCGGCGGTCTTGAAAC-3′
  • Barley gene Bl5C (800 bp) was amplified with the primers 5′- 5′-CGGATCCCGTCATCCTCTTCTCGCACCCC-3′ and 5′-GGAATTCCCTTCTTGGAGGGCAGGTCGGCG-3′.
  • Mitochondrial D-loop fragment (800-900 bp) was amplified with the primers HV2 described by Hoelzel et al., 1991, Mol. Biol. Evol., 8, 475-493, and the primer 5′-GGTGACTTGCATGTGTAAGTTCA-3′.
  • the amplified fragments were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 ⁇ TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • DNA yield of 300-500 ng was routinely obtained from fish epithelia, using the standard protocol and one sample test (Table 2). Mitochondrial DNA was nicely amplified using 5% of the isolated DNA.

Abstract

The present invention provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample. Where the method of the invention is used to isolate DNA, it may conveniently be couple with a further step to isolate RNA from the same sample.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application is a continuation of co-pending U.S. patent application Ser. No. 11/234,001 filed Sep. 23, 2005, which was a continuation of U.S. patent application Ser. No. 08/849,686 filed Aug. 21, 1997, which was a 35 U.S.C. § 371 national phase filing of international application No. PCT/GB95/02893, filed Dec. 12, 1995, which claimed priority to GB 9425138.6, filed Dec. 12, 1994.
  • DESCRIPTION
  • The present invention relates to the isolation of nucleic acid, and especially to the isolation of DNA or RNA from cells.
  • The isolation of DNA or RNA is an important step in many biochemical and diagnostic procedures. For example, the separation of nucleic acids from the complex mixtures in which they are often found is frequently necessary before other studies and procedures e.g. detection, cloning, sequencing, amplification, hybridisation, cDNA synthesis etc. can be undertaken; the presence of large amounts of cellular or other contaminating material eg. proteins or carbohydrates, in such complex mixtures often impedes many of the reactions and techniques used in molecular biology. In addition, DNA may contaminate RNA preparations and vice versa. Thus, methods for the isolation of nucleic acids from complex mixtures such as cells, tissues etc. are demanded, not only from the preparative point of view, but also in the many methods in use today which rely on the identification of DNA or RNA eg. diagnosis of microbial infections, forensic science, tissue and blood typing, detection of genetic variations etc.
  • In RNA identifications it is important for a conclusive diagnosis to be certain that the detected sequence is derived from an RNA molecule and not from genomic DNA contamination in the sample. For this reason, methods for the separation of RNA from DNA are important. Also, for RNA isolation rapid methods are required since RNA molecules usually are very unstable and rapidly degraded by RNases present in cells and body fluids. The quality of the RNA is probably the most important factor in determining the quality of the final results in protocols utilising mRNA, especially for cDNA synthesis. It is important to avoid DNA contamination of RNA preparations for a number of reasons. Firstly, DNA increases viscosity making sample handling difficult leading to poor RNA yield and also RNA of poor quality with the likelihood of DNA contamination. Also, DNA contamination may trap RNase enzymes and make downstream applications such as RT-PCR worthless.
  • A range of methods are known for the isolation of nucleic acids, but generally speaking, these rely on a complex series of extraction and washing steps and are time consuming and laborious to perform. Moreover, the use of materials such as alcohols and other organic solvents, chaotropes and proteinases is often involved, which is disadvantageous since such materials tend to interfere with many enzymatic reactions and other downstream processing applications.
  • Thus, classical methods for the isolation of nucleic acids from complex starting materials such as blood or blood products or tissues involves lysis of the biological material by a detergent or chaotrope, possibly in the presence of protein degrading enzymes, followed by several extractions with organic solvents eg. phenol and/or chloroform, ethanol precipitation, centrifugations and dialysis of the nucleic acids. The purification of RNA from DNA may involve a selective precipitation with LiCl or a selective isolation with acidic guanidinium thiocyanate combined with phenol extractions and ethanol precipitation. Not only are such methods cumbersome and time consuming to perform, but the relatively large number of steps required increases the risk of degradation, sample loss or cross-contamination of samples where several samples are simultaneously processed. In the case of RNA isolation, the risk of DNA contamination is relatively high.
  • In purification of RNA, it is commonly desired to specifically isolate mRNA. Most mRNA purification strategies involve isolation of total RNA and fractionation of the isolated RNA. Preparation of high-quality mRNA is an important step in the analysis of gene structure and gene regulation.
  • Most eukaryotic mRNAs have a poly(A)tail, typically about 50 to 300 nucleotides long. Such mRNA is referred to as polyadenylated or poly(A)+ mRNA. In separating this polyadenylated RNA from the non-adenylated RNA which accounts for 95% or more of a cell's total RNA, advantage is taken of this poly(A) tail and some type of affinity separation directed toward the poly(A) tail is performed. The conventional technology has involved purification of total RNA as a first step and selection of poly(A)+ RNA by affinity chromatography using oligo(dT)-cellulose as the second step. This strategy, is rather time-consuming and labour-intensive. An alternative strategy for mRNA purification is to use oligo(dT) linked to solid supports such as microplates, latex, agarose or magnetic beads.
  • Over the past four years it has become increasingly popular to employ a magnetic bead assisted strategy for poly(A)+ RNA selection since such beads have proven to be favourable in mRNA manipulations. In many approaches, the yield and the quality of the products depends on how rapidly the mRNA can be purified from nucleases and other contaminants. By using the magnetic bead separation technology, pure, intact poly(A)+ RNA can be obtained rapidly either from total RNA preparations or more importantly, directly from crude lysates of solid tissues, cell or body fluids. The entire procedure can be carried out in a microfuge tube without phenol extractions or ethanol precipitations.
  • One approach common in RNA purification, which may be used in conjunction with the solid phase approach is to carry out the lysis of the biological material and the subsequent hybridisation to oligo dT in LiCl and LiDS/SDS buffers, thereby avoiding extra steps such as phenol extraction or proteinase-K digestion. The whole direct mRNA isolation takes approximately 15 minutes and since the mRNA is stable for more than 30 minutes in the lysis buffer, this ensures the high quality of the mRNA purified. However, a disadvantage of this method is that mRNA per weight unit of tissue is affected by the amount of tissue used and above a critical threshold of lysed cells, the yield of mRNA decreases.
  • Another common approach for direct mRNA purification is, as mentioned above, to use guanidinium isothiocyanate (GTC) and sarkosyl. A GTC-buffer system is preferred by most researchers due to the ability of this chaotropic salt to inhibit RNases. This may also be used in combination with the magnetic bead approach. However, the viscosity of cell lysates in 4M GTC is high and the beads are not effectively attracted by the magnet, resulting in an increased risk for DNA contamination, both for beads and other solid phases, and lower yields.
  • More recently, other methods have been proposed which rely upon the use of a solid phase. In U.S. Pat. No. 5,234,809, for example, is described a method where nucleic acids are bound to a solid phase in the form of silica particles, in the presence of a chaotropic agent such as a guanidinium salt, and thereby separated from the remainder of the sample. WO 91/12079 describes a method whereby nucleic acid is trapped on the surface of a solid phase by precipitation. Generally speaking, alcohols and salts are used as precipitants.
  • Although such methods speed up the nucleic acid separation process, there are disadvantages associated with the use of alcohols, chaotropes, and other similar agents. Chaotropes require to be used at high molarity, resulting in viscous solutions which may be difficult to work with, especially in RNA work. Amplification procedures such as PCR, and other enzyme-based reactions, are very sensitive to the inhibitory or otherwise interfering effects of alcohols and other agents. Moreover, the drying of the nucleic acid pellet which is necessary following alcohol precipitation and the problems with dissolving nucleic acids, are also known to lead to artifacts in enzyme-based procedures such as PCR. Since such procedures are now a mainstay of molecular biology, there is a need for improved methods of nucleic acid isolation, and particularly for methods which are quick and simple to perform and which avoid the use of chaotropic agents or alcohol precipitation. There is also a need for a method which allows for differentiation between RNA and DNA and permits a separate isolation of both types of nucleic acid from the same sample. The present invention seeks to provide such methods.
  • In particular, it has now been found that nucleic acid may be isolated from a sample in a form suitable for amplification or other downstream processes, by a simple and easy to perform procedure which involves treating the sample with detergent and allowing the nucleic acid to bind to a solid support, whereupon the nucleic acid may be readily separated from the sample, eg. by removal of the support. The binding of the nucleic acid is independent of its sequence.
  • In one aspect, the present invention thus provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample.
  • The nucleic acid may be DNA, RNA or any naturally occurring or synthetic modification thereof, and combinations thereof. Preferably however the nucleic acid will be DNA, which may be genomic, or, cDNA, and single or double stranded or in any other form.
  • Where the method of the invention is used to isolate DNA, it may conveniently be coupled with a further step to isolate RNA from the same sample. The use of the method in such two-step RNA separations will be described in more detail below.
  • The samples may be any material containing nucleic acid, including for example foods and allied products, clinical and environmental samples. However, the sample will generally be a biological sample, which may contain any viral or cellular material, including all prokaryotic or eukaryotic cells, viruses, bacteriophages, mycoplasmas, protoplasts and organelles. Such biological material may thus comprise all types of mammalian and non-mammalian animal cells, plant cells, algae including blue-green algae, fungi, bacteria, protozoa etc. Representative samples thus include whole blood and blood-derived products such as plasma, serum and buffy coat, urine, feces, cerebrospinal fluid or any other body fluids, tissues, cell cultures, cell suspensions etc.
  • The sample may also include relatively pure starting materials such as a PCR product, or semi-pure preparations obtained by other nucleic acid recovery processes.
  • The nucleic acid-containing sample may, generally speaking, simply be contacted with the detergent, and a solid phase which may be added to the sample prior to, simultaneously with, or subsequently to the detergent. If necessary, this may be preceded by one or more separate steps to disrupt structural components such as cell walls or to achieve lysis. Procedures for achieving this are well known in the art. Thus, for example, although some cells eg. blood cells, may be lysed by the detergent alone, other cells, eg. plant or fungal cells or solid animal tissues may require more vigorous treatment such as, for example, grinding in liquid nitrogen, heating in the presence of detergent, alkaline lysis in the presence of detergent. For samples in the form of paraffin sections and such like, lysis (and melting of the paraffin) may be effected by heating, for example using a microwave oven (Banerjee, S. K. ea., 1995, Biotechniques 18: 769-773). Also, certain more compact tissues may require enzyme treatment, for example using proteinase K to obtain sufficient release of nucleic acid. The various components are mixed and simply allowed to stand for a suitable interval of time to allow the nucleic acid to bind to the support. Conveniently, if other agents such as enzymes eg. proteinase K are being used, they may be included in with the detergent. The support is then removed from the solution by any convenient means, which will depend of course on the nature of the support, and includes all forms of withdrawing the support away from the sample supernatant, or vice versa, for example centrifugation, decanting, pipetting etc.
  • The conditions during this process are not critical, and it has been found convenient, for example, simply to mix the sample with the detergent in the presence of a solid phase, and allow it to stand at room temperature, for 5 to 20 minutes, before separating. As mentioned above, the reaction time is not critical and as little as 5 minutes is often enough. However, if convenient, longer periods may be used, eg. 0.5 to 3 hours, or even overnight. Mixing can be done by any convenient means, including for example simple agitation by stirring or vortexing. Also, if desired, higher or lower temperatures may be used, but are not necessary.
  • The detergent may be any detergent, and a vast range are known and described in the literature. Thus, the detergent may be ionic, including anionic and cationic, non-ionic or zwitterionic. The term “ionic detergent” as used herein includes any detergent which is partly or wholly in ionic form when dissolved in water. Anionic detergents have been shown to work particularly well and are preferred. Suitable anionic detergents include for example sodium dodecyl sulphate (SDS) or other alkali metal alkylsulphate salts or similar detergents, sarkosyl, or combinations thereof.
  • Conveniently, the detergent may be used in a concentration of 0.2 to 30% (w/v), eg. 0.5 to 30%, preferably 0.5 to 15%, more preferably 1 to 10%. For anionic detergents concentrations of 1.0 to 5% eg. 0.5 to 5% have been shown to work well.
  • The detergent may be supplied in simple aqueous solution, which may be alkaline or acidic, or more preferably in a buffer. Any suitable buffer may be used, including for example Tris, Bicine, Tricine, and phosphate buffers. Conveniently, a source of monovalent cations, eg. a salt, may be included to enhance nucleic acid capture, although this is not necessary. Suitable salts include chloride salts, e.g. sodium chloride, lithium chloride etc. at concentrations of 0.1 to 1M, eg. 250 to 500 mM. As mentioned above, other components such as enzymes, may also be included.
  • Other optional components in the detergent composition include chelating agents eg. EDTA, EGTA and other polyamino carboxylic acids conveniently at concentrations of 1 to 50 mM etc., reducing agents such as dithiotreitol (DTT) or β-mercaptoethanol, at concentrations of for example 1 to 10 mM.
  • Preferred detergent compositions may for example comprise:
  • 100 mM Tris-HCl pH 7.5
  • 10 mM EDTA
  • 2% SDS
  • or:
  • 100 mM TrisCl pH 7.5
  • 10 mM EDTA
  • 5% SDS
  • 10 mM NaCl
  • or:
  • 100 mM TrisCl pH 7.5
  • 500 mM LiCl
  • 10 mM EDTA
  • 1% LiDS
  • The detergent functions in the method to lyse the nucleic acid containing material, eg. the cells and nuclei to release the nucleic acid. The detergent is also believed to help to disrupt the binding of proteins, eg. DNA-binding proteins, to the nucleic acid and to reduce the problem of contaminants in the sample sticking to the solid support.
  • The solid support may be any of the well known supports or matrices which are currently widely used or proposed for immobilisation, separation etc. These may take the form of particles, sheets, gels, filters, membranes, fibers, capillaries, or microtitre strips, tubes, plates or wells etc.
  • Conveniently the support may be made of glass, silica, latex or a polymeric material. Preferred are materials presenting a high surface area for binding of the nucleic acid. Although not wishing to be bound by theoretical considerations, it is believed that the nucleic acid binding process may be assisted by the nucleic acid “wrapping around” the support. Such supports will generally have an irregular surface and may be for example be porous or particulate eg. particles, fibres, webs, sinters or sieves. Particulate materials eg. beads are generally preferred due to their greater binding capacity, particularly polymeric beads.
  • Conveniently, a particulate solid support used according to the invention will comprise spherical beads. The size of the beads is not critical, but they may for example be of the order of diameter of at least 1 and preferably at least 2 μm, and have a maximum diameter of preferably not more than 10 and more preferably not more than 6 μm. For example, beads of diameter 2.8 μm and 4.5 μm have been shown to work well.
  • Monodisperse particles, that is those which are substantially uniform in size (eg. size having a diameter standard deviation of less than 5%) have the advantage that they provide very uniform reproducibility of reaction. Monodisperse polymer particles produced by the technique described in U.S. Pat. No. 4,336,173 are especially suitable.
  • Non-magnetic polymer beads suitable for use in the method of the invention are available from Dyno Particles AS (Lillestrom, Norway) as well as from Qiagen, Pharmacia and Serotec.
  • However, to aid manipulation and separation, magnetic beads are preferred. The term “magnetic” as used herein means that the support is capable of having a magnetic moment imparted to it when placed in a magnetic field, and thus is displaceable under the action of that field. In other words, a support comprising magnetic particles may readily be removed by magnetic aggregation, which provides a quick, simple and efficient way of separating the particles following the nucleic acid binding step, and is a far less rigorous method than traditional techniques such as centrifugation which generate shear forces which may degrade nucleic acids.
  • Thus, using the method of the invention, the magnetic particles with nucleic acid attached may be removed onto a suitable surface by application of a magnetic field eg. using a permanent magnet. It is usually sufficient to apply a magnet to the side of the vessel containing the sample mixture to aggregate the particles to the wall of the vessel and to pour away the remainder of the sample.
  • Especially preferred are superparamagnetic particles for example those described by Sintef in EP-A-106873, as magnetic aggregation and clumping of the particles during reaction can be avoided, thus ensuring uniform and nucleic acid extraction. The well-known magnetic particles sold by Dynal AS (Oslo, Norway) as DYNABEADS, are particularly suited to use in the present invention.
  • Functionalised coated particles for use in the present invention may be prepared by modification of the beads according to U.S. Pat. Nos. 4,336,173, 4,459,378 and 4,654,267. Thus, beads, or other supports, may be prepared having different types of functionalised surface, for example positively charged or hydrophobic. Weakly and strongly positively charged surfaces, weakly negatively charged neutral surfaces and hydrophobic surfaces eg. polyurethane-coated have been shown to work well.
  • It is also possible to use solid supports which have been modified to permit the selective capture of desired cells, viruses etc. containing the nucleic acid. Thus for example, supports carrying antibodies, or other binding proteins, specific for a desired cell type may be used. This may introduce a degree of selectivity to the isolation of the nucleic acid, since only nucleic acid from a desired target source within a complex mixture may be separated. Thus for example, such a support may be used to separate and remove the desired cell type etc. from the sample, following which, the detergent is added to achieve lysis, release of the nucleic acid, and binding to the support.
  • The preparation of such selective cell capture matrices is well known in the art and described in the literature.
  • Likewise, the support may be provided with binding partners to assist in the selective capture of nucleic acids. For example, complementary DNA or RNA sequences, or DNA binding proteins may be used, or viral proteins binding to viral nucleic acid. The attachment of such proteins to the solid support may be achieved using techniques well known in the art.
  • Although not necessary, it may be convenient to introduce one or more washing steps to the isolation method of the invention, for example following separation of the support from the sample. In the case of magnetic beads, this may conveniently be done before releasing the DNA from the beads. Any conventional washing buffers or other media may be used. Generally speaking, low to moderate ionic strength buffers are preferred eg. 10 mM Tris-HCl at pH 8.0/10 mM NaCl. Other standard washing media, eg. containing alcohols, may also be used, if desired.
  • Following the separation step, and any optional washing steps which may be desired, the support carrying the nucleic acid may be transferred eg. resuspended or immersed into any suitable medium eg. water or low ionic strength buffer. Depending on the support and the nature of any subsequent processing desired, it may or may not be desirable to release the nucleic acid from the support.
  • In the case of a particulate solid support such as magnetic or non-magnetic beads, this may in many cases be used directly, for example in PCR or other amplifications, without eluting the nucleic acid from the support. Also, for many DNA detection or identification methods elution is not necessary since although the DNA may be randomly in contact with the bead surface and bound at a number of points by hydrogen bonding or ionic or other forces, there will generally be sufficient lengths of DNA available for hybridisation to oligonucleotides and for amplification.
  • However, if desired, elution of the nucleic acid may readily be achieved using known means, for example by heating, eg. to 65° C. for 5 to 10 minutes, and following which the support may be removed from the medium leaving the nucleic acid in solution. Such heating is automatically obtained in PCR by the DNA denaturation step preceding the cycling program.
  • If it is desired to remove RNA from DNA, this may be achieved by destroying the RNA before the DNA separation step, for example by addition of an RNase or an alkali such as NaOH.
  • Alternatively, as mentioned above, the method of the invention may be used to separate sequentially DNA and RNA from the sample. It may also be used to remove DNA from a sample in an RNA purification procedure.
  • Conveniently, the sequential separation may take place using two different solid phases, for example solid supports which can differentiate between DNA and RNA. Thus, such a method may comprise carrying out a first step separation to isolate DNA as described above. A further solid support can then be added to the sample to capture the RNA remaining in the sample, either by using a solid support that can bind the RNA or any remaining nucleic acid, or a solid support that can capture specific RNA molecules (eg. by carrying a complementary nucleic acid probe), or a subset of RNA molecules eg. polyadenylated RNA. In this way it is possible rapidly to isolate and separate DNA and RNA or subsets of both from the same sample. This may be useful, for example by measuring the isolated DNA to estimate the amount of cells used for RNA extraction, which will give a reference between different samples.
  • However, the DNA isolation procedure of the invention may also readily be combined, as a preliminary step, with other conventional RNA purification procedures, for example DNA isolation with detergent according to invention may be carried out before a selective RNA precipitation step, for example using LiCl or before RNA separation using GTC and sarkosyl.
  • In a representative procedure, the sample is lysed in the presence of detergent and the DNA is allowed to bind to a solid support, whereupon the DNA may readily be separated from the sample by removal of the support. If desired, the DNA can rapidly and easily be further handled for amplification or other downstream processes. The RNA may then be isolated. This can be by a solid phase based system as described above, including a repetition of the method of the invention, or by conventional techniques such as extractions, precipitations or affinity chromatography.
  • A particularly advantageous embodiment of the invention is to use the isolation method of the invention to remove DNA from a sample prior to isolation of RNA, such that the viscosity of the lysed sample is reduced and a specific isolation of RNA molecules is favored which again reduces or avoids the possibility for DNA contamination of the RNA. Such a method also has the advantage of being quick to perform.
  • The invention is advantageously amenable to automation, particularly if particles, and especially, magnetic particles are used as the support.
  • The various reactants and components required to perform the method of the invention may conveniently be supplied in kit form. Such kits represent a further aspect of the invention.
  • At its simplest, this aspect of the invention provides a kit for isolating nucleic acid from a sample comprising a solid support and one or more detergents.
  • Optionally included in such a kit may be buffers, salts, lysis agents eg. proteinases, chelating agents and reducing agents.
  • For isolation of RNA, the kits may further comprise means for isolating RNA eg. a second solid support for isolating RNA, for example a support provided with probes for capture of RNA eg. oligo dT or probes of complementary sequence to the desired target, or a chaotrope or selective precipitating agent.
  • DESCRIPTION OF THE FIGURES
  • The invention will now be described in more detail in the following non-limiting Examples with reference to the drawings in which:
  • FIG. 1 shows as optical density scan of DNA isolated as described in Example 1 (ordinate shows absorbance (OD), abscissa shows wavelength (nM)). Maximum absorbance (0.427) at 257.6 nM; minimum absorbance (0.292) at 236.4 nM; at a threshold of 0.100;
  • FIG. 2 shows gel electrophoresis of a sample of DNA isolated as described in Example 1 (lane 1: isolation; lane 2: .lamda. Hind III (molecular weight marker));
  • FIG. 3 shows agarose gel electrophoresis of the PCR product of Example 2 (lane 1: PCR product; lane 2: .lamda. Hind III; lane 3: negative PCR control); and
  • FIG. 4 shows agarose gel electrophoresis of the PCR product of Example 5 (lane 1: .lamda. Hind III; lanes 2 and 3: isolations A and B respectively; lanes 4 and 5: negative control; lane 6: .lamda. Hind III).
  • FIG. 5 show the comparison between traditionally isolated DNA and DNA isolated with Dynabeads DNA DIRECT. Panel I shows the amount of genomic DNA isolated from 10 μl of whole blood with Dynabeads DNA DIRECT including the optional elution step (lanes 1 and 2), with Dynabeads DNA DIRECT with the elution step omitted (lanes 3 and 4), and with traditional DNA isolation (lanes 5 and 6). The molecular weight marker in lane 7 is .lamda. HindIII. Panel II shows the integrity of DNA isolated by Dynabeads DNA DIRECT. Lanes 1 and 2 show AMXY PCR from 20 ng of DNA isolated with Dynabeads DNA DIRECT from a male and female donor respectively. Lanes 4 and 5 show AMXY PCR from 200 ng DNA isolated by traditional methods from a female and a male donor respectively. Lane 3 is the negative control.
  • FIG. 6 shows the reproducibility of Dynabeads DNA DIRECT. The figure shows five independent Dynabeads DNA DIRECT isolations from each of two donors. Half of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Molecular weight markers are .lamda. HindIII (lanes marked M) or 100 bp ladder (lane marked L).
  • FIG. 7 shows the effect of different anticoagulants. The figure shows Dynabeads DNA DIRECT isolations from whole blood that is not anticoagulated and from blood anticoagulated with EDTA, citrate, or S heparin. The two isolations from blood with the same anticoagulant were performed on blood from different donors (A or B). One quarter of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, except for heparin, where half the DNA obtained from 5 μl is shown. 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure, except for heparin, where 20% of the isolated DNA was used as starting material.
  • FIG. 8 shows the effect of sample storage conditions. Panel I shows Dynabeads DNA DIRECT isolations from EDTA blood that has been used fresh, refrigerated for 4 days, or frozen for 4 days. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Panel II shows Dynabeads DNA DIRECT isolations from citrate blood that has been used fresh or air dried and rehydrated. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
  • FIG. 9 shows Dynabeads DNA DIRECT from bone marrow and culture cells. Panel I shows Dynabeads DNA DIRECT isolations from 1, 2 and 5 μl of bone marrow from each of two donors. A or B above the lanes denote the identity of the donor. Half of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Panel II shows two Dynabeads DNA DIRECT isolations from 4×105 Daudi cells. One tenth of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 1 μl of a total of 120 μl isolated DNA is shown in the lower part of the figure. The molecular weight marker is .lamda. HindIII for the genomic DNA and 100 bp ladder for the PCR products.
  • FIG. 10 shows Dynabeads DNA DIRECT from formalin fixed, paraffin embedded material. Lane A is 20% of the PCR product from a reaction started with DNA isolated by DNA DIRECT from a formalin fixed, paraffin embedded section of liver. Lane M is molecular weight marker (100 bp ladder), lane B is positive control (PCR from 20 ng human DNA), and lane C is negative control (PCR from water).
  • FIG. 11 shows Dynabeads DNA DIRECT for mRNA purification. mRNA was isolated from 1 million Daudi cells per sample with Dynabeads Oligo(dT)25 after removal of DNA with Dynabeads DNA DIRECT. Increasing amounts of DNA DIRECT Dynabeads were used to remove genomic DNA; 1 mg in lane 1 and 2; 2 mg in lane 3 and 4; 5 mg in lane 5 and 6 and 10 mg in lane 7 and 8. Lane 9 and 10 are controls where no DNA was removed before direct mRNA purification. The extra bands on the top of the picture show contaminating genomic DNA in lane 9 and 10. The two strong bands in all lanes represent ribosomal RNA.
  • FIG. 12 shows the results of DNA isolation and PCR amplification from (A) bacteria, (B) fungi, (C) algae and (D) plants. For all samples, DNA was isolated with 200 μl DNA DIRECT (one sample test) and 20% of the isolated DNA and 10% of the PCR products were analysed by agarose electrophoresis. For bacteria, 2.5% of the isolated DNA was used per PCR reaction, for the other samples 5% was used. 16S rRNA regions were amplified from bacterial genomic DNA and from algae chloroplast DNA. From fungi- and algae genomic DNA, 18S rDNA were amplified. Amplification of the group I intron chloroplast trnL and parts of the genomic B15C gene are shown for plants. The negative controls are PCR on samples without DNA prepared in the same way as the other reactions.
  • EXAMPLES Example 1
  • DNA Isolation from Cell Culture
  • 4×106 HL60 cells were washed twice in PBS and pelleted. The pellet was dissolved in 10 μl PBS, and 1 mg of Dynabeads® M-280* obtainable by autoclaving a suspension of Dynabeads® M-280 tosyl activated (available from DYNAL A/S, Oslo, Norway) in water) resuspended in 0.1 ml lysis buffer [5% SDS/10 mM TrisCl pH 8.0/1 mM EDTA] was added. This was followed immediately by the addition of 1 ml lysis buffer, and the suspension was incubated for 5 minutes at room temperature, after which the Dynabeads®, with bound DNA was attracted to a magnet and the liquid phase removed. The solid phase was then washed twice with 1 ml washing buffer [50 mM NaCl/10 mM TrisCl pH 8.0/1 mM EDTA]. Finally, the beads, with bound DNA, were resuspended in 0.1 ml water, and incubated for 5 minutes at 65° C. The beads were attracted to a magnet, and the liquid phase withdrawn. The liquid phase was then analyzed for its DNA content. Results from an optical density scan (FIG. 1) are in accordance with pure DNA. The OD260/OD280 ratio is 1.72; pure DNA in water or TE has a ratio of 1.7-1.9. With pure DNA, the concentration can be determined from the OD260 of the solution. A 50 μg/ml solution has OD260=1.0. From the OD260 measurement (Table 1) of 0.436 (0.1 ml total volume, 10 mm light path), the yield can be calculated to 2.18 μg DNA, 82% of the 2.67 μg that was the estimated DNA content of the starting material. Gel electrophoresis of a sample of the isolated DNA (FIG. 2) shows that most of it is in a high molecular weight form (>20 kb).
    TABLE 1
    PERKIN-ELMER LAMBDA BIO UV/VIS SPECTROMETER
    APPLICATION NO. 3: RATIO 260/280 NM
    WAVELENGTH
    SAMPLE CYCLE AUTOZERO DATA UNIT
    004 15:50 260.0 nm 0.436 ABS
    15:56 280.0 nm 0.253 ABS
    RATIO 1.723 RAT
  • Example 2
  • Isolation of DNA from Whole Blood and Enzymatic Application without Elution
  • 5 μl whole blood (EDTA blood) was lysed in 50 μl 5% SDS and 50 μg Dynabeads® M-280* in 5 μl of PBS was added. The lysate was incubated for 1 minute at room temperature before 0.5 ml TrisCl pH 7.5 was added. The lysate was then incubated for 1 minute further at room temperature before the beads with bound DNA were attracted to a magnet and the liquid phase removed. The beads were then washed once with 0.5 ml 10 mM TrisCl pH 7.5, before the beads with bound DNA was resuspended in 40 μl TE (10 mM TrisCl pH 8.0/1 mM EDTA). 4 μl of the isolation was used in starting material for PCR (GAPDH PCR as described in Example 7). The PCR reaction gave large amounts of product, as visualised on agarose gel electrophoresis (FIG. 3). 10 μl of a 50 μl PCR reaction was loaded on the gel.
  • Example 3
  • Example 1 was repeated using the following combination of lysis buffers and washing buffers, and the following results were obtained:
    Lysis buffer Washing buffer Result
    2% SDS  50 mM NaCl/1 × TE +++
    2% SDS/1 × TE  50 mM NaCl/1 × TE +++
    2% SDS/1 × TE/10 mM NaCl  50 mM NaCl/1 × TE +++
    5% SDS  50 mM NaCl/1 × TE +++
    5% SDS/1 × TE  50 mM NaCl/1 × TE +++
    5% SDS/1 × TE/10 mM NaCl  50 mM NaCl/1 × TE +++
    1% LiDS/10 × TE/0.5 M LiCl  50 mM NaCl/1 × TE +++
    1% LiDS/10 × TE/0.5 M LiCl 150 mM LiCl/1 × TE +++
    5% LiDS 150 mM LiCl/1 × TE +++
    5% SDS 150 mM LiCl/1 × TE +++
    1% Sarcosyl 150 mM LiCl/1 × TE +++

    1 × TE is 10 mM TrisCl pH 8.0/1 mM EDTA.

    10 × TE is 100 mM TrisCl pH 8.0/10 mM EDTA.

    where +++ indicates very good DNA isolation.
  • Example 4
  • Following the procedure of Example 1, similar results may be achieved using Dynabeads® M-450 uncoated (Dynal A/S, Oslo, Norway)
  • Example 5
  • Isolation of DNA from CD2 Positive Cells Obtained from Blood with Immunomagnetic Separation
  • This experiment consisted of two identical isolations. 50 μl blood was mixed with 50 μl PBS [150 mM NaCl/10 mM NaH2PO4/Na2HPO4, pH 7.4] and 10 μl (4×106 beads) Dynabeads® M-450 Pan-T (CD2) (available from Dynal AS, Oslo, Norway). The mixture was then incubated for 30 minutes at room temperature with gentle tilting and rotation. The cell/beads complex was attracted to a magnet and the fluid withdrawn. The cell/beads complex was then washed four times in 200 μl PBS, before 200 g Dynabeads® M-280* (as above) and 2001 lysis buffer [100 mM Tris-HCl, pH 8.0/500 mM LiCl/10 mM EDTA, pH 8.01/1% LiDS] was added. The mixture was incubated for 5 minutes at room temperature, before the DNA/beads complex was attracted to a magnet, and the supernatant withdrawn. The DNA/beads complex washed twice with 200 μl washing buffer [10 mM Tris-Hcl, pH 8.0/150 mM LiCl/1 mM EDTA, pH 8.0] and resuspended in 50 μl water. After 5 minutes at 65° C., the beads were attracted to a magnet and the supernatant transferred to a new tube. 5 μl of the supernatant was used as template for polymerase chain reaction (GAPDH PCR as described in Example 7), which gave large amounts of product, as visualised on agarose gel electrophoresis (FIG. 4).
  • Example 6
  • Comparison of Yield and Integrity Between DNA Isolated by a Traditional Method and the Present Method
  • Using a traditional method based on phenol extraction and ethanol precipitation, genomic DNA was isolated from 5 ml of EDTA anticoagulated blood. Four isolations from 10 μl of the same blood sample were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway, containing beads equivalent to Dynabeads® M-280* as described in Example 1). The DNA from two of the isolations was eluted for 5 minutes at 65° C., while the DNA from the other two isolations was left in the presence of the Dynabeads. All the DNA from the four Dynabeads DNA DIRECT isolations was loaded onto an agarose gel, as was 0.2% of traditionally isolated DNA. The fraction of the traditionally isolated DNA loaded corresponds to the yield from 10 μl of blood (0.2% of 5 ml).
  • Traditional DNA isolation was performed according to the method of John and coworkers (John, S. W. M., G. Weitzner, R. Rosen and C. R. Scriver. 1991. A Rapid Procedure for Extracting Genomic DNA from Leukocytes. Nucl. Acid. Res. 19(2):408).
  • With Dynabeads DNA DIRECT, lysis of the blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with 10 μl of blood in a 1.5 ml microcentrifuge tube (200 μg uncoated Dynabeads in Lysis/binding buffer). Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 μl of TE pH 8.0 (provided in the kit).
  • When elution was performed, it consisted of heating the suspension to 65° C. for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the experiments.
  • The DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • The result of this experiment is shown in panel I of FIG. 5. The yield per μl blood is similar with the two methods (lane 1-4 vs lane 5-6), and very little DNA is lost during the elution step (lane 1-2 vs lane 3-4). The molecular weight of the DNA from both methods is more than 20 kb, as it runs slower than the 23.13 kb band of the .lamda. HindIII molecular weight marker.
  • DNA DIRECT was used to isolate DNA from ACD blood from two different donors, one male and one female. From each of the isolations, 10% was used as starting material for PCR amplification of an amplicon in the X-Y homologous amelogenin (AMXY) gene (Akane, A., K, Matsubara, H. Nakamura, S. Takahashi and K. Kimura. 1994. Purification of Highly Degraded DNA by Gel Filtration for PCR. BioTechniques 16 (2):235-238), as was 200 ng from each of two traditional DNA isolations.
  • DNA DIRECT and traditional DNA isolation was performed as described in the first part of this example.
  • All PCR reactions were performed in a 50 μl reaction volume, 10×PCR buffer (Perkin Elmer) was added to a final concentration of 1×, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers AMXY-1F (5′-CTGATGGTTGGCCTCAAGCCT-GTG-3′) and AMXY-4R (5′-TTCATTGTAAGAGCAAAGCAAACA-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the AMXY amplicon were 4 min at 94° C., 38×[30 sec at 94° C., 30 sec at 55° C., 1 min at 72° C.], 10 min at 72° C.
  • 10 μl of the 50 μl PCR reactions were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • The results of this experiment are shown in panel II of FIG. 5. The X-Y homologous amelogenin gene is known to be sensitive to DNA degradation (Akane et al 1994, supra). With increasing degradation, the 908 bp long X band gets progressively weaker as compared to the 719 bp long Y band. From panel II of FIG. 5 it is apparent that the relative strength of the X and Y bands is comparable for DNA isolated with Dynabeads DNA DIRECT and the traditional method, indicating that the degree of degradation is the same with the two methods. The PCR reactions from traditionally isolated DNA gives somewhat more product than does the reactions from DNA DIRECT isolated DNA. The reason for this is that ten times more template is used in the PCR reactions from traditionally isolated DNA than in the PCR reactions from DNA DIRECT isolated DNA.
    Lysis/binding buffer: 0.5 M LiCl
    1% LiDS
    0.1 M TrisCl pH 7.5
    10 mM EDTA
    5 mM dithiothreitol (DTT)
    Washing buffer: 0.15 M LiCl
    10 mM Tris-HCl pH 8.0
    1 mM EDTA
  • Example 7
  • Five Independent DNA Isolations from Blood Samples from Each of Two Donors
  • For this experiment, we used Dynabeads DNA DIRECT kit, which is commercially available from Dynal AS, Oslo, Norway. Buffer compositions are as described in example 6.
  • Five DNA isolations were performed from each of two citrate treated blood samples of relatively low white blood cell counts (sample A: 3.6×106 cells/ml, sample B: 2.6×106 cells/ml).
  • Lysis of the blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit). This resuspension was used for PCR and gel electrophoresis without any elution.
  • From each isolation, 10% was used as starting material for PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. All PCR reactions were performed in a 50 μl reaction volume, 10×PCR buffer (Perkin Elmer) was added to a final concentration of 1×, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers GAPDH-Forward (5′-ACAGTCCATGCCATCACTGCC-3′) and GAPDH-Reverse (5′-GCCTGCTTCACCACCCTTG-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94° C., 34×[30 sec at 94° C., 30 sec at 61° C., 1 min at 72° C.], 10 min at 72° C.
  • Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • The results of this experiment are shown in FIG. 6. No significant variation between the different isolations can be observed. Similar results were obtained with other coagulants as well as from donors with higher white blood cell counts.
  • Example 8
  • DNA Isolation from Blood with Different Anticoagulants
  • Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from untreated whole blood as well as blood anticoagulated with EDTA, Citrate or Heparin. From each type of starting material, two separate isolations were performed, with blood from different donors. The buffer components in the kit are as described in example 6.
  • Lysis of the DNA containing cells from blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with 5 μl Heparin blood or 10 μl of other blood samples in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 20-40 μl of TE pH 8.0 (provided in the kit). We used 40 μl as the standard volume, but 20 μl if the starting material was Heparin blood.
  • From each isolation, 10% (20% from the Heparin samples) was used as starting material for PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. PCR was performed directly on the suspension in TE, with the Dynabeads present. All PCR reactions were performed in a 50 μl reaction volume, 10×PCR buffer (Perkin Elmer) was added to a final concentration of 1×, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 μmol each of primers GAPDH-Forward (5′-ACAGTCCATGCCATCACTGCC-3′) and GAPDH-Reverse (5′-GCCTGCTTCACCACCTTCTTG-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94° C., 34×[30 sec at 94° C., 30 sec at 61° C., 1 min at 72° C.], 10 min at 72° C.
  • 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 25% (50% from the Heparin samples) of the isolated genomic DNA. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • The results of this experiment are shown in FIG. 7. As the isolations from Heparinized samples were from only 5 μl of blood, using 20% of the DNA from these isolations as starting material for PCR is comparable to using 10% from the other isolations, that are all from 10 μl blood. When this is taken into consideration, it is apparent that the type of anticoagulant used does not significantly affect the result.
  • In the experiment just described, Lithium Heparin was used. In this system, similar results are obtained with Lithium and Sodium Heparin, even though Lithium Heparin has been shown to have inhibitory effects in other systems (Panaccio, M., M. Georgesz and A. M. Lew. 1993. FOLT PCR: A Simple PCR Protocol for Amplifying DNA Directly from Whole Blood. BioTechniques 14(3): 238-243). DNA DIRECT also performs well on blood anticoagulated with ACD (panel II of FIG. 5) or CPD (data not shown).
  • Example 9
  • Isolation of DNA from Blood Samples Stored Under Different Conditions
  • Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from EDTA blood from two different donors: What was remaining of the blood samples were then divided into two, one part that was stored at +4° C. and one that was stored at −20° C. After 4 days, the frozen samples were thawed, and DNA was isolated from both the frozen samples and the samples that had been kept at +4° C. The buffer components of the kit are as described in example 6.
  • Lysis of the blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
  • From each of the 6 isolations (fresh, refrigerated, and frozen), 10% was used as starting material for PCR amplification of the GAPDR amplicon as described in example 8. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on the gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The results of this experiment are shown in panel I of FIG. 8. No adverse effect of 4 days storage at +4 or −20° C. was observed in this system.
  • Using Dynabeads DNA DIRECT as described earlier in this example, DNA was isolated from two citrate treated blood samples, and from the same two samples 10 μl was spotted on a plastic surface and allowed to air dry at room temperature. The dried blood spots were transferred to 1.5 ml tubes, 40 μl PBS was added, and the tubes were left at room temperature with gentle agitation for 90 min, before DNA was isolated with Dynabeads DNA DIRECT. From each of the 4 isolations (fresh and dried), 10% was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on the gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The results of this experiment are shown in panel II of FIG. 8. The yield from dried blood is good and the isolated DNA is suitable for PCR.
  • Example 10
  • DNA Isolation from Bone Marrow and Culture Cells
  • DNA Isolations from Bone Marrow
  • 1, 2, and 5 μl of heparinized bone marrow from each of two healthy donors were used as starting material for DNA isolation with DNA DIRECT. The buffer components are as described in example 6. Lysis of the bone marrow was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with 1-5 μl of heparinized bone marrow in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
  • The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E(MPC-E)), and the lysate was aspirated and discarded.
  • The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
  • From each of the 6 isolations, 10% was used as starting material for PCR amplification of the GAPDH amplicon as is described in example 8.
  • Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • The results of this experiment are shown in panel I of FIG. 9. It is apparent from panel I of FIG. 9 that the yield per volume starting material is higher from bone marrow than from blood (FIGS. 5-8). This is to be expected, since the concentration of DNA containing cells is much higher in bone marrow than in blood. 5 μl of bone marrow is close to the upper limit of what can be handled by 1 sample test of DNA DIRECT. A good correlation between sample size and DNA yield is observed in the 1 to 5 μl sample size interval, but even the yield from 1 μl is sufficient for at least 10 PCR reactions.
  • DNA Isolation from Cultured Cells
  • Two samples of 4×105 Daudi cells were used as starting material for DNA isolation with DNA DIRECT. DNA isolation from 4×105 cultured cells (cell line Daudi) was performed as described above, except that 1 ml (five sample tests) of Dynabeads DNA DIRECT was used. Accordingly, the washing steps were performed in 1 ml washing buffer. The DNA/Dynabeads complex was resuspended in 120 μl TE, and as for bone marrow, no elution step was performed after the resuspension.
  • From each of the isolations, 1 μl of a total of 120 μl was used as starting material for PCR amplification of the GAPDH amplicon, as described in Example 8.
  • Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 10% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • The results of this experiment are shown in panel II of FIG. 9, demonstrating that at least 120 PCR reactions may be run from an isolation of this scale.
  • Example 11
  • Isolation of DNA from a Formalin Fixed, Paraffin Embedded Section of Liver
  • Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from a formalin fixed, paraffin embedded section of liver. The buffer components of the kit and the bead concentration are as described in example 6.
  • Excess paraffin was removed from the edges of the sample with a scalpel blade. Lysis of the sample was obtained by adding 200 μl (one sample test) of Dynabeads DNA DIRECT to the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads. The lysate, containing DNA and Dynabeads was transferred to a fresh tube, leaving cell debris and paraffin behind.
  • The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 μl of sterile water. This suspension, with the Dynabeads present, was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8. The PCR product was visualised on an ethidium bromide stained 1.5% agarose gel. 10 μl of the 50 μl reaction was loaded on the gel. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The result of this experiment is shown in FIG. 10. PCR amplifiable material has clearly been obtained from the formalin fixed, paraffin embedded section of liver.
  • Example 12
  • Removal of Genomic DNA with DNA DIRECT Prior to mRNA Isolation
  • mRNA was isolated from 1 million Daudi cells per sample. The cells were lysed in 0.75 ml Lysis/binding buffer with DNA DIRECT Dynabeads present in the buffer. The samples were incubated for 5 minutes and the DNA-Dynabead complexes were collected by applying a Dynal MPC-E magnet for 2 minutes. Different amounts of DNA DIRECT beads were used to remove genomic DNA; 1, 2, 5 and 10 mg per sample (FIG. 11).
  • The lysate from each sample was transferred to new tubes with 1 mg Dynabeads Oligo(dT)25 according to standard procedure (Dynals mRNA DIRECT kit protocol). The Dynabeads were mixed with the lysate to capture the polyadenylated mRNA by hybridisation for 5 minutes at room temperature. The mRNA-Dynabead complexes were collected with the MPC-E magnet by placing the tubes in the magnetic stand for 2 minutes. The solution was removed and discarded. Washing solution with LiDS (0.75 ml) was added and the beads were washed thoroughly by pipetting up and down. The mRNA-Dynabead complexes were collected with the magnet, and the washing procedure was repeated once with washing buffer with LiDS and twice with washing buffer without detergent. Finally, the purified mRNA was eluted from the Dynabeads in 20 μl 5 mM Tris-HCl pH 7.5 buffer, by incubation at 65° C. for 2 minutes. The eluates were analysed by non-denaturing gel electrophoresis in a 1.0 t agarose gel with ethidium bromide. FIG. 11 shows the results from this experiment.
  • The EtBr-staining reveals both double-stranded DNA and rRNA due to secondary structure. The two ribosomal RNA bands are clearly visible in all lanes. In Lane 9-10 in FIG. 11, some genomic DNA is present as contamination after the mRNA purification procedure. In the recommended mRNA procedure from DYNAL, a DNA-shearing step is introduced after cell lysis, to reduce the possibility of DNA contamination. By using DNA removal with DNA DIRECT beads this shearing step is not necessary.
    Lysis/binding buffer: 0.5 M LiCl
    1% LiDS
    0.1 M TrisCl pH 7.5
    10 mM EDTA
    5 mM dithiothreitol (DTT)
    Washing buffer with LiDS: 0.15 M LiCl
    0.1% LiDS
    10 mM Tris-HCl pH 8.0
    1 mM EDTA
    Washing buffer: 0.15 M LiCl
    10 mM Tris-HCl pH 8.0
    1 mM EDTA
  • Example 13
  • Universal Method for DNA Isolation
  • PCR-Ready DNA from Bacteria, Fungi, Algae, Plants and Vertebrates
  • E. coli and Baceillus cereus were grown overnight at 37° C. in LB medium, Agrobacterium tumefaciens was grown overnight in YEB medium for about 40 hours at 28° C. (Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbour Laboratory, NY.). Cyanobacteria and Prochlorthrix were grown in NIVA medium for 14 days at 18° C. using an illumination of 20 micro Einstein (Norwegian Institute of Water Research, 1991, Culture collection of algae). 20-200 million bacteria or 450,000 cyanobacteria were used per DNA isolation.
  • Agar plates containing 2% malt extract was used for mycelia growth and incubated for 14 days at room temperature. Mycelia was isolated by scraping the surface of the agar plates with a spatula. Fungi fruitbodies were obtained from natural populations. In the range of 1-3 mg air dried and 3-20 mg fresh fungi fruitbodies were used per DNA isolation.
  • Bakers yeast Saccharomyces cerevisiae was obtained from a commercial supplier. Algae were cultured under illumination in IMR-medium for 7 days (Eppley, R et al., 1967, Exp. Mar. Biol. Ecol. 1, 191-208). Fresh leaves from Arabidopsis thaliana and barley (Hordeum vulgare) were picked from young plants (3 weeks old). Epithelia were obtained from perch (Perca fluvatilis) fins. About 1 mg wet weight yeast, 30-100 mg young plant leaves and 100-400 mg perch were used per DNA isolation.
  • Multicellular tissues with rigid cell walls were mechanically broken to increase DNA yield. Fungi fruitbodies were ground with forceps for about 2 minutes. Plant leaves were homogenised for 2 minutes in liquid nitrogen with a pestle (Kontes Scientific Instruments, Vineland, N.J., USA). For all other samples no mechanical work was required for cell breakage.
  • DNA Isolation
  • DNA isolations were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway). Lysis of the cells and organisms were obtained by mixing 200 μl of Dynabeads DNA DIRECT (200 μg uncoated Dynabeads in Lysis/binding buffer) with the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 to 15 minutes to allow adsorption of genomic DNA to the Dynabeads. For some bacteria and for plants, incubation at 65° C. for 15 minutes was used to improve lysis before the adsorption step.
  • The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
  • The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit) by vigorous pipetting. Elution was performed by heating the suspension to 65° C. for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the experiments.
  • The DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
    Lysis/binding buffer: 0.5 M LiCl
    1% LiDS
    0.1 M TrisCl pH 7.5
    10 mM EDTA
    5 mM dithiothreitol (DTT)
    Washing buffer: 0.15 M LiCl
    10 mM Tris-HCl pH 8.0
    1 mm EDTA
  • For an evaluation of the yield from the DNA DIRECT isolation protocol, standard phenol/chloroform based methods were used. Algae, vertebrate and bacterial DNA were isolated with the protocol described by Sambrook, J. et al., 1989, supra. Cyanobacteria were homogenized with alumina type A-5 (Sigma Chemicals Co., St. Louis, USA) before isolation to ensure complete lysis. Plant and fungi DNA were isolated with the protocol described by Scot, O. R. and Bendich, A. J., 1994, in “Plant Molecular Biology Manual”, page D1: 1-8, Kluwer Academic Publisher, Belgium. PCR Amplifications
  • For each sample type the reproducibility was tested by using separate DNA isolations, serial DNA dilutions and multiple PCR assays. DNA isolation reagents and PCR reagents were controlled for absence of contamination in each separate experiment. All PCR reactions were performed in a 50 μl reaction volume containing; μmoles primers, 200 μM dNTP, 10 mM Tris-HCl pH 8.8, 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100, 1 Unit DynaZyme thermostable polymerase (Finnzymes Oy, Finland) and 0.1-5 μl of isolated DNA. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600.
  • Amplicons and Oligonucleotide Primer
  • All PCR reactions were started with a DNA denaturation step at 94-97° C. for 3 to 5 minutes and ended with an extension step at 72° C. for 5 minutes.
  • Bacteria and Algae:
  • The amplicon was a 16S rRNA region corresponding to E. coli base 334 to 939 according to IUD numbering from bacteria and algae chloroplasts (Brosius, J., et al., 1978, Proc. Natl. Acad. Sci., USA, 57, 4801-4805).
  • Primers:
    CC 5′-TGTAAAACGACGGCCAGTCCAGACTCCTACGGGAGGCAGC-3
    CD
    5′-CTTGTGCGGGCCCCCGTCAATTC-3′
  • Primer CC has a 5′ end complementary to −21 M13 universal primer, making it suitable for direct DNA sequencing. Amplification: 30 cycles of 96° C. for 15 seconds and 70° C. for 2 minutes.
  • Algae:
  • An 18S rRNA region was amplified with the primers A and B described by Medlin et al., 1990, Gene, 71, 491-499.
  • Amplification:
  • 35 cycles of 94° C. for 30 seconds, 50° C. for 1 minute and 72° C. for 1 minute.
  • Fungi:
  • A 18S rRNA region (ca. 600 bp.) was amplified with the primers NS3 and NS4 as described by White et al., 1990. In “PCR Products, a Guide to Methods and Applications” by Innis, M. A. et al., page 315-322, Academic Press, New York.
  • Amplification:
  • 5 cycles of 94° C. for 30 seconds, 53° C. for 30 seconds and 72° C. for 1 minute; followed by 25 cycles of 94° C. for 30 seconds, 50° C. for 30 seconds increasing with 15 seconds for each cycle, and 72° C. for 1 minute.
  • Plants:
  • The tRNL group I intron in chloroplasts were amplified with the primers C and D described by Fangan et al., 1994, BioTechniques 16, 484-494.
  • Amplification:
  • 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds and 72° C. for 1 minute.
  • A part of the Arabidopsis thaliana gene BI5C (800 bp) was amplified with the primers:
    5′-CGGGATCCCTAGGAGACACGGCCG-3′
    and
    5′-GGAATTCGATCGGCGGTCTTGAAAC-3′
  • Amplification:
  • 35 cycles of 94° C. for 30 seconds, 59° C. for 30 seconds and 72° C. for 1 minute.
  • A part of the Barley gene Bl5C (800 bp) was amplified with the primers 5′-
    5′-CGGATCCCGTCATCCTCTTCTCGCACCCC-3′
    and
    5′-GGAATTCCCTTCTTGGAGGGCAGGTCGGCG-3′.
  • Amplification:
  • 35 cycles of 94° C. for 30 seconds, 60° C. for 30 seconds and 72° C. for 1 minute.
  • Perch:
  • Mitochondrial D-loop fragment (800-900 bp) was amplified with the primers HV2 described by Hoelzel et al., 1991, Mol. Biol. Evol., 8, 475-493, and the primer 5′-GGTGACTTGCATGTGTAAGTTCA-3′.
  • Amplification:
  • 30 cycles of 96° C. for 1 minute, 52° C. for 2 minutes and 72° C. for 2 minutes.
  • The amplified fragments were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
  • The results of the experiments are shown in FIG. 12 and Table 2.
  • Bacteria:
  • The standard protocol gave DNA yields in the range of 100-1000 ng for the bacteria tested (FIG. 12A). For some Cyanobacteria there was a substantial increase in DNA yield (from 500 ng to more than 1 mg) by improving the lysis with an extra initial incubation step at 65° C. for 15 minutes. In all cases, good amplifications were obtained by using 0.25% of the isolated DNA.
  • Fungi:
  • The highest DNA yield was obtained from dried fruit-bodies (300-500 ng) compared with fresh fruit bodies (100-200 ng) (FIG. 12B). Mycelia gave low DNA recovery probably due to low number of cells per sample. However, in most cases 5% of the isolated DNA was enough to give nice PCR products (Table 2, FIG. 12B). For fruit bodies, 0.5-5% of DNA was used for each PCR.
  • Algae:
  • All algae tested gave DNA yield in the range of 200-400 ng using the standard protocol and 1 DNA DIRECT sample test (Table 2, FIG. 12C). Nice PCR results were obtained both for amplification of genomic DNA and chloroplast DNA by using 5% of the isolated DNA per PCR reaction.
  • Plants:
  • To obtain good DNA yield from plant leaves homogenization in liquid nitrogen was necessary. An extra initial incubation step at 65° C. for 15 minutes also improved the results (FIG. 12D). Nice PCR results were obtained both for amplification of genomic DNA and chloroplast DNA, when 5% of the isolated DNA was used per PCR reaction.
  • Fish:
  • DNA yield of 300-500 ng was routinely obtained from fish epithelia, using the standard protocol and one sample test (Table 2). Mitochondrial DNA was nicely amplified using 5% of the isolated DNA.
  • PCR products from all species tested could easily be directly sequenced by solid-phase sequencing (Hultman et al., 1989, Nucleic Acids Res., 17, 4937-4946).
    TABLE 2
    DNA isolation and PCR amplification from different organisms
    DNA Amplicon PCR
    Species Sample yield Gen. Org. productd
    Bacteria
    Bacillus sereus gram pos. fresh +++ 16S +++
    AH 75a
    E. coli gram pos. fresh +++ 16S +++
    NovaBlue
    A. tumefaciens gram neg. fresh +++ 16S +++
    GV 310
    Planlaothrix gram neg. fresh +++ 16S +++
    agardhill Cyanobacteria
    N-C29
    P. prolifica gram neg. fresh +++ 16S +++
    N-C320 Cyanobacteria
    Microstysis gram neg. fresh +++ 16S +++
    aruginosa Cyanobactena
    N-C 43
    M. aruginosa gram neg. fresh +++ 16S +++
    N-C 228/1 Cyanobacteria
    Anabana bory gram neg. frozen +++ 16S ++
    N-C 246 Cyanobacteria
    Phomidium sp gram neg. frozen +++ 16S ++
    N-C 177 Cyanobacteria
    Apha- gram neg. frozen +++ 16S +++
    nizomenon sp Cyanobacteria
    N-C 103
    P. hollandica gram neg. frozen ++ 16S +++
    N 5/89 prochlorothrix
    Fungi
    Corrinarius basidlomycetes d. fruith +++ 16S +++
    sanguineus
    Corinarius basidlomycetes d. fruith nt 16S +++
    gentillis
    Rusula inegra basidlomycetes f. fruith ++ 16S +++
    Laccaria ascomycetes f. mycel + 16S +++
    bicolor
    Triharia ascomycetes f. mycel nt 16S +++
    ochroleuca
    Verjahinia ascomycetes f. mycel nt 16S +++
    cahhae
    Peziza yeast f. mycel nt 16S +++
    vesiculosa
    Saccharomyces yeast fresh + 16S +++
    cervisiae
    Algae
    Gyrodinum dinoflagellates fresh +++ 16S/16S +++/+++
    aureolum
    Hetrocania dinoflagellates fresh +++ 16S/16S +++/+++
    triguera
    Scripsiella dinoflagellates fresh +++ 16S/16S +++/+++
    prochiden
    Ceranium dinoflagellates fresh +++ 16S +++
    stricum
    Chorella dinoflagellates fresh +++ 16S +++
    vulgaris
    Clamydomonas chlorophyta fresh +++ 16S +++
    reinardii
    Callacanius phacophycease fresh +++ 16S +++
    ustilla
    Chryso- crysophycease fresh +++ 16S +++
    chromulina
    polyelepis
    Plants
    Hordum monocot leaf +++ B15C/trnL +++/+++
    vulgare
    (barley)
    Arabidopsis dicot leaf +++ B15C/trnL +++/+++
    thaliana
    Vertebrates
    Perca fish ep. +++ D-loop +++
    fubvatillis
    (perch)

    a A. rumerifaciens = Aghrobacterium tumefaciens, P. hollandica = Prochlorothrix hollandica.

    bd. fruitb = dried fruitbodies, f. mycelia = fresh mycalia, ep. = epithelium.

    cApproximate DNA yields relalive to standard phenol/chloroform isolations; +++: >80%, ++: >10%, +: >1%, nt. = not tested.

    dGen. = genomic DNA, Org. = organelle DNA from chloreplasts (algae and plants) and mitochondria (fish).

    eAmplicons as described in example 13.

Claims (20)

1. A method of isolating genomic DNA from a sample comprising cells, wherein the genomic DNA is present in the cells, the method comprising (a) contacting the sample with a solid support comprising an organic polymer, wherein the solid support selectively binds the cells, (b) contacting the cells bound to the solid support with a detergent in the absence of any chaotropic agent, whereby soluble genomic DNA becomes bound to the support in a sequence-independent manner in the presence of the detergent and absence of any chaotropic agent, and (c) separating the support with bound genomic DNA from the sample.
2. The method of claim 1, wherein the solid support comprises an antibody or binding protein specific for the cells.
3. The method of claim 1, wherein the solid support comprises an antibody specific for CD2 positive cells.
4. The method of claim 1, wherein the detergent is anionic.
5. The method of claim 1, wherein the detergent is sodium dodecyl sulphate, or another alkali metal alkylsulphate salt, or sarkosyl.
6. The method of claim 1, wherein the concentration of detergent is 0.2% to 30% (w/v).
7. The method of claim 1, wherein the detergent is contained in a composition additionally comprising one or more monovalent cations, chelating agents or reducing agents.
8. The method of claim 1, wherein the detergent is used in alkaline solution.
9. The method of claim 1, wherein the solid support is particulate.
10. The method of claim 1, wherein the solid support comprises magnetic beads.
11. The method of claim 1, wherein the solid support has a hydrophobic surface.
12. The method of claim 1, wherein the genomic DNA is eluted from the support, following separation from the sample.
13. The method of claim 12, wherein the genomic DNA is eluted by heating.
14. The method of claim 1, wherein the organic polymer is polyurethane.
15. The method of claim 1, wherein the organic polymer is polystyrene.
16. The method of claim 1, wherein the organic polymer is latex.
17. The method of claim 1, wherein the solid support comprises superparamagnetic polystyrene beads.
18. The method of claim 1, wherein the solid support is porous.
19. The method of claim 1, further comprising the step of detecting, hybridizing, amplifying or quantifying the bound genomic DNA after the separating step.
20. A method of isolating RNA and genomic DNA from a sample comprising cells, wherein the RNA and genomic DNA are present inside the cells, the method comprising (a) contacting the sample with a solid support comprising an organic polymer, wherein the solid support selectively binds the cells, (b) contacting the cells bound to the support with a detergent in the absence of any chaotropic agent, whereby soluble genomic DNA in the sample is bound to the support in a sequence-independent manner in the presence of the detergent and absence of any chaotropic agent; (c) separating the support with bound genomic DNA from the sample; and (d) isolating RNA from the sample.
US11/671,426 1994-12-12 2007-02-05 Isolation of nucleic acid Abandoned US20070190559A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US11/671,426 US20070190559A1 (en) 1994-12-12 2007-02-05 Isolation of nucleic acid
US12/054,332 US7989614B2 (en) 1994-12-12 2008-03-24 Isolation of nucleic acid
US12/130,959 US20090149646A1 (en) 1994-12-12 2008-05-30 Isolation of Nucleic Acid
US12/130,926 US20090068724A1 (en) 1994-12-12 2008-05-30 Isolation of Nucleic Acid
US13/160,428 US8691969B2 (en) 1994-12-12 2011-06-14 Isolation of nucleic acid
US14/183,999 US20140291576A1 (en) 1994-12-12 2014-02-19 Isolation of nucleic acid

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9425138.6 1994-12-12
GBGB9425138.6A GB9425138D0 (en) 1994-12-12 1994-12-12 Isolation of nucleic acid
US08/849,686 US20040215011A1 (en) 1994-12-12 1995-12-12 Isolation of nucleic acid
PCT/GB1995/002893 WO1996018731A2 (en) 1994-12-12 1995-12-12 Isolation of nucleic acid
US11/234,001 US7173124B2 (en) 1994-12-12 2005-09-23 Isolation of nucleic acid
US11/671,426 US20070190559A1 (en) 1994-12-12 2007-02-05 Isolation of nucleic acid

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/234,001 Continuation US7173124B2 (en) 1994-12-12 2005-09-23 Isolation of nucleic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/054,332 Continuation US7989614B2 (en) 1994-12-12 2008-03-24 Isolation of nucleic acid

Publications (1)

Publication Number Publication Date
US20070190559A1 true US20070190559A1 (en) 2007-08-16

Family

ID=10765877

Family Applications (8)

Application Number Title Priority Date Filing Date
US08/849,686 Abandoned US20040215011A1 (en) 1994-12-12 1995-12-12 Isolation of nucleic acid
US11/234,001 Expired - Fee Related US7173124B2 (en) 1994-12-12 2005-09-23 Isolation of nucleic acid
US11/671,426 Abandoned US20070190559A1 (en) 1994-12-12 2007-02-05 Isolation of nucleic acid
US12/054,332 Expired - Fee Related US7989614B2 (en) 1994-12-12 2008-03-24 Isolation of nucleic acid
US12/130,926 Abandoned US20090068724A1 (en) 1994-12-12 2008-05-30 Isolation of Nucleic Acid
US12/130,959 Abandoned US20090149646A1 (en) 1994-12-12 2008-05-30 Isolation of Nucleic Acid
US13/160,428 Expired - Fee Related US8691969B2 (en) 1994-12-12 2011-06-14 Isolation of nucleic acid
US14/183,999 Abandoned US20140291576A1 (en) 1994-12-12 2014-02-19 Isolation of nucleic acid

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/849,686 Abandoned US20040215011A1 (en) 1994-12-12 1995-12-12 Isolation of nucleic acid
US11/234,001 Expired - Fee Related US7173124B2 (en) 1994-12-12 2005-09-23 Isolation of nucleic acid

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/054,332 Expired - Fee Related US7989614B2 (en) 1994-12-12 2008-03-24 Isolation of nucleic acid
US12/130,926 Abandoned US20090068724A1 (en) 1994-12-12 2008-05-30 Isolation of Nucleic Acid
US12/130,959 Abandoned US20090149646A1 (en) 1994-12-12 2008-05-30 Isolation of Nucleic Acid
US13/160,428 Expired - Fee Related US8691969B2 (en) 1994-12-12 2011-06-14 Isolation of nucleic acid
US14/183,999 Abandoned US20140291576A1 (en) 1994-12-12 2014-02-19 Isolation of nucleic acid

Country Status (9)

Country Link
US (8) US20040215011A1 (en)
EP (1) EP0796327B1 (en)
JP (1) JP3787354B2 (en)
AT (1) ATE272110T1 (en)
AU (1) AU706211B2 (en)
CA (1) CA2207608C (en)
DE (1) DE69533317T2 (en)
GB (1) GB9425138D0 (en)
WO (1) WO1996018731A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040444A1 (en) * 2007-09-28 2009-04-02 Mole Genetics As Rna isolation method
US20110104157A1 (en) * 2008-04-04 2011-05-05 Chugai Seiyaku Kabushiki Kaisha Liver cancer drug
US7989614B2 (en) 1994-12-12 2011-08-02 Invitrogen Dynal As Isolation of nucleic acid
US8110351B2 (en) 2002-01-16 2012-02-07 Invitrogen Dynal As Method for isolating nucleic acids and protein from a single sample

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2965131B2 (en) 1995-07-07 1999-10-18 東洋紡績株式会社 Magnetic carrier for nucleic acid binding and nucleic acid isolation method using the same
DE69734263T2 (en) * 1996-07-12 2006-07-13 Toyo Boseki K.K. Process for isolating ribonucleic acids.
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
GB9709728D0 (en) * 1997-05-13 1997-07-02 Dynal As Single step method
JP2001516731A (en) 1997-09-17 2001-10-02 ジエントラ・システムズ・インコーポレーテツド Apparatus and method for isolating nucleic acids
EP2290099B1 (en) 1998-02-02 2012-10-10 QIAGEN North American Holdings, Inc. Processes for isolating, amplifying and characterizing DNA
AU2574499A (en) * 1998-02-02 1999-08-16 Gentra Systems, Inc. Compositions and methods for using a lysing matrix for isolating dna
WO1999039009A1 (en) * 1998-02-02 1999-08-05 Gentra Systems, Inc. Processes for isolating, amplifying and characterizing dna
US6534262B1 (en) 1998-05-14 2003-03-18 Whitehead Institute For Biomedical Research Solid phase technique for selectively isolating nucleic acids
US6291179B1 (en) * 1998-09-10 2001-09-18 Whatman Plc Product and method for separation of a sample containing multiple sources of genetic material using a solid medium
US5973138A (en) * 1998-10-30 1999-10-26 Becton Dickinson And Company Method for purification and manipulation of nucleic acids using paramagnetic particles
FI990082A0 (en) * 1999-01-18 1999-01-18 Labsystems Oy Purification process using magnetic particles
US7790865B1 (en) 1999-02-02 2010-09-07 Qiagen North American Holdings, Inc Eluting reagents, methods and kits for isolating DNA
WO2000053807A1 (en) * 1999-03-11 2000-09-14 Whatman, Inc. Solid medium and process for the storage and rapid purification of nucleic acid
WO2000063362A1 (en) * 1999-04-21 2000-10-26 Annovis, Inc. Magnetic dna extraction kit for plants
ATE320443T1 (en) * 1999-07-15 2006-04-15 Qiagen Gmbh METHOD FOR SEPARATING PARTICLE SUBSTRATES FROM A SOLUTION BY MINIMIZING PARTICLE LOSS
US6936414B2 (en) 1999-12-22 2005-08-30 Abbott Laboratories Nucleic acid isolation method and kit
GB0001450D0 (en) 2000-01-21 2000-03-08 Genpoint As Cell isolation method
GB0013658D0 (en) * 2000-06-05 2000-07-26 Dynal Asa Nucleic acid isolation
EP1978110B1 (en) * 2000-09-06 2010-05-26 Transnetyx, Inc. Computer-based method and system for screening genomic DNA
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
JP2004508057A (en) * 2000-09-06 2004-03-18 ホッジ ティモシー エイ System, method and apparatus for screening for transgenic and target specific mutations
US20020106686A1 (en) * 2001-01-09 2002-08-08 Mckernan Kevin J. Methods and reagents for the isolation of nucleic acids
US6692700B2 (en) 2001-02-14 2004-02-17 Handylab, Inc. Heat-reduction methods and systems related to microfluidic devices
US7829025B2 (en) 2001-03-28 2010-11-09 Venture Lending & Leasing Iv, Inc. Systems and methods for thermal actuation of microfluidic devices
US8895311B1 (en) 2001-03-28 2014-11-25 Handylab, Inc. Methods and systems for control of general purpose microfluidic devices
EP1416047A4 (en) * 2001-07-09 2007-03-14 Asahi Chemical Ind Method of purifying nucleic acid using nonwoven fabric and detection method
US7893228B2 (en) 2001-10-12 2011-02-22 Qiagen North American Holdings, Inc. Compositions and methods for using a solid support to purify RNA
US7148343B2 (en) 2001-10-12 2006-12-12 Gentra Systems, Inc. Compositions and methods for using a solid support to purify RNA
US20050032105A1 (en) 2001-10-12 2005-02-10 Bair Robert Jackson Compositions and methods for using a solid support to purify DNA
KR100445560B1 (en) * 2001-10-31 2004-08-21 (주)바이오넥스 Method of manufacturing kit for isolating nucleic acids or biological materials, kit manufactured by the method, and apparatus using the kit
JP4106026B2 (en) * 2001-11-28 2008-06-25 アプレラ コーポレイション Selective nucleic acid isolation methods and compositions
JP4148900B2 (en) 2002-01-08 2008-09-10 エフ.ホフマン−ラ ロシュ アーゲー Use of silica materials in amplification reactions
US7786295B2 (en) 2002-02-15 2010-08-31 Qiegen North American Holdings, Inc Method to isolate DNA
GB0212826D0 (en) 2002-05-31 2002-07-10 Dna Res Innovations Ltd Materials and methods relating to polyions and substance delivery
GB0215185D0 (en) 2002-07-01 2002-08-07 Genovision As Binding a target substance
EP1388588B1 (en) * 2002-07-29 2008-09-17 JSR Corporation Nucleic acid-separating method and nucleic acid-extracting reagent
US20060094015A1 (en) 2002-10-04 2006-05-04 Whatman Inc. Methods and materials for using chemical compounds as a tool for nucleic acid storage on media of nucleic acid purification systems
US20040180445A1 (en) * 2003-03-12 2004-09-16 Domanico Michael J. Methods and compositions for purification of nucleic acid from a host cell
WO2004108925A1 (en) * 2003-06-04 2004-12-16 Qiagen As Method for sequentially isolating dna and rna from the same nucleic acid-containing sample
US20050059054A1 (en) 2003-07-25 2005-03-17 Richard Conrad Methods and compositions for preparing RNA from a fixed sample
EP2402089A1 (en) 2003-07-31 2012-01-04 Handylab, Inc. Processing particle-containing samples
WO2005108620A2 (en) * 2004-05-03 2005-11-17 Handylab, Inc. Processing polynucleotide-containing samples
US8852862B2 (en) 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
ES2529044T3 (en) * 2004-05-21 2015-02-16 Mo Bio Laboratories, Inc. Kits and procedures to remove nucleic acid contaminants in environmental and biological samples
US20060024712A1 (en) * 2004-06-25 2006-02-02 Invitrogen Corporation Separation of nucleic acid
US7527929B2 (en) 2004-07-30 2009-05-05 Agencourt Bioscience Corporation Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers
JP5390772B2 (en) 2004-11-05 2014-01-15 キアゲン ノース アメリカン ホールディングス, インコーポレイテッド Compositions and methods for purifying nucleic acids from stabilizing reagents
US20060166223A1 (en) * 2005-01-26 2006-07-27 Reed Michael W DNA purification and analysis on nanoengineered surfaces
EP1856282A4 (en) 2005-02-15 2009-05-13 Univ Virginia Nucleic acid isolation methods and materials and devices thereof
CA2871777C (en) * 2005-03-10 2015-07-28 Matthew J. Hayes System and methods for detecting multiple optical signals
CN101213619A (en) * 2005-06-23 2008-07-02 西门子医疗系统诊断股份有限公司 Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use
DE102005047736B4 (en) * 2005-09-29 2008-08-14 Aj Innuscreen Gmbh Method and system for isolating nucleic acids from any complex starting materials
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US7998708B2 (en) 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
EP2001990B1 (en) 2006-03-24 2016-06-29 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US20100216657A1 (en) * 2006-05-16 2010-08-26 Arcxis Biotechnologies, Inc. Pcr-free sample preparation and detection systems for high speed biologic analysis and identification
WO2008002882A2 (en) * 2006-06-26 2008-01-03 Blood Cell Storage, Inc. Device and method for extraction and analysis of nucleic acids from biological samples
US20080003575A1 (en) * 2006-06-28 2008-01-03 Sigma-Aldrich Co. Methods and composition for RNA extraction
DE102006032610C5 (en) * 2006-07-11 2016-09-15 Aj Innuscreen Gmbh Method for the parallel isolation of viral nucleic acids
US10131935B2 (en) 2006-07-11 2018-11-20 Aj Innuscreen Gmbh Method for parallel isolation of viral nucleic acids
CN103497991A (en) 2006-11-06 2014-01-08 科隆迪亚戈有限公司 Device and method for analysis using binding members
WO2008061165A2 (en) 2006-11-14 2008-05-22 Handylab, Inc. Microfluidic cartridge and method of making same
WO2008060604A2 (en) 2006-11-14 2008-05-22 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US20100190240A1 (en) * 2007-03-21 2010-07-29 Ibis Biosciences, Inc. Reagents for nucleic acid purification
CA2629589C (en) 2007-04-20 2016-03-29 F.Hoffmann-La Roche Ag Isolation and purification of nucleic acid molecules with a solid phase
JP5232858B2 (en) * 2007-06-29 2013-07-10 ベクトン・ディキンソン・アンド・カンパニー Method for extracting and purifying components of biological samples
US8182763B2 (en) 2007-07-13 2012-05-22 Handylab, Inc. Rack for sample tubes and reagent holders
EP3741869A1 (en) 2007-07-13 2020-11-25 Handylab, Inc. Polynucleotide capture materials and methods of using same
US8105783B2 (en) 2007-07-13 2012-01-31 Handylab, Inc. Microfluidic cartridge
US9618139B2 (en) 2007-07-13 2017-04-11 Handylab, Inc. Integrated heater and magnetic separator
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US8287820B2 (en) 2007-07-13 2012-10-16 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
CA2722242C (en) 2007-07-23 2018-07-17 Clondiag Gmbh Methods and devices for determining values indicative of the presence and/or amount of nucleic acids
EP2191012A1 (en) * 2007-09-21 2010-06-02 Streck, Inc. Nucleic acid isolation in preserved whole blood
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
EP3144672B1 (en) 2007-11-21 2018-08-22 Cosmosid Inc. Genome identification system
WO2009117167A1 (en) * 2008-01-02 2009-09-24 Blood Cell Storage, Inc. Devices and processes for nucleic acid extraction
CN104531673B (en) 2008-02-15 2018-03-16 生命科技公司 Method and kit for DNA extractions
DE102008010693A1 (en) 2008-02-22 2009-08-27 Qiagen Gmbh New matrix materials, processes for their preparation and their use in methods of isolating biomolecules
DE102008010692A1 (en) 2008-02-22 2009-08-27 Qiagen Gmbh New matrices, processes for their preparation and their use in methods of isolating biomolecules
DE102008029356A1 (en) * 2008-06-20 2009-12-24 Siemens Healthcare Diagnostics Gmbh Process for the purification of nucleic acids, in particular from fixed tissue
USD787087S1 (en) 2008-07-14 2017-05-16 Handylab, Inc. Housing
JP2012508015A (en) * 2008-11-04 2012-04-05 ブラッド・セル・ストレイジ,インコーポレイテッド Nucleic acid extraction on curved glass surfaces
CN102105587A (en) 2009-01-16 2011-06-22 爱科来株式会社 Process for producing nucleic acid sample, and process for producing nucleic acid amplification product using the nucleic acid sample
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
WO2011026030A1 (en) * 2009-08-31 2011-03-03 Mbio Diagnostics Corporation Integrated sample preparation and analyte detection
US20110223588A1 (en) * 2010-03-09 2011-09-15 Biosample Llc Solid Phase Nucleic Acid Extraction From Small Sample Volumes, and Release of Controlled Quantities
ES2665012T3 (en) 2010-06-29 2018-04-24 Exscale Biospecimen Solutions Ab Procedure and kit for sequential isolation of nucleotide species from a sample
US8747084B2 (en) 2010-07-21 2014-06-10 Aperia Technologies, Inc. Peristaltic pump
US11031095B2 (en) 2010-08-06 2021-06-08 Ariosa Diagnostics, Inc. Assay systems for determination of fetal copy number variation
US10533223B2 (en) 2010-08-06 2020-01-14 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US20140342940A1 (en) 2011-01-25 2014-11-20 Ariosa Diagnostics, Inc. Detection of Target Nucleic Acids using Hybridization
US10167508B2 (en) 2010-08-06 2019-01-01 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
US11203786B2 (en) 2010-08-06 2021-12-21 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US20130040375A1 (en) 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US20130261003A1 (en) 2010-08-06 2013-10-03 Ariosa Diagnostics, In. Ligation-based detection of genetic variants
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
GB201020095D0 (en) 2010-11-26 2011-01-12 Invitrogen Dynal As Nucleic acid preparation method
AU2012207442B2 (en) * 2011-01-18 2017-02-23 Everist Genomics, Inc. Prognostic signature for colorectal cancer recurrence
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
US9994897B2 (en) 2013-03-08 2018-06-12 Ariosa Diagnostics, Inc. Non-invasive fetal sex determination
US8756020B2 (en) 2011-01-25 2014-06-17 Ariosa Diagnostics, Inc. Enhanced risk probabilities using biomolecule estimations
US11270781B2 (en) 2011-01-25 2022-03-08 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
CA2833262C (en) 2011-04-15 2020-08-18 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
WO2012159063A2 (en) 2011-05-19 2012-11-22 Blood Cell Strorage, Inc. Gravity flow fluidic device for nucleic acid extraction
EP2546199A1 (en) 2011-07-14 2013-01-16 Université Catholique De Louvain Solid iron oxide support for isolation of microorganisms
JP5924888B2 (en) * 2011-08-26 2016-05-25 関東化學株式会社 Nucleic acid extraction method, nucleic acid extraction reagent kit, and nucleic acid extraction reagent
US8712697B2 (en) 2011-09-07 2014-04-29 Ariosa Diagnostics, Inc. Determination of copy number variations using binomial probability calculations
USD692162S1 (en) 2011-09-30 2013-10-22 Becton, Dickinson And Company Single piece reagent holder
KR102121853B1 (en) 2011-09-30 2020-06-12 벡톤 디킨슨 앤드 컴퍼니 Unitized reagent strip
US9766207B2 (en) 2011-11-04 2017-09-19 Bio-Rad Laboratories, Inc. Affinity methods and compositions employing electronic control of pH
CN104040238B (en) 2011-11-04 2017-06-27 汉迪拉布公司 Polynucleotides sample preparation apparatus
EP2773221B1 (en) * 2011-11-04 2019-01-09 Bio-Rad Laboratories, Inc. Simultaneous purification of cell components
CA2859697C (en) * 2011-12-21 2021-06-08 Geneohm Sciences Canada Inc. Enrichment & isolation of microbial cells & microbial nucleic acids from a biological sample
CA2863637C (en) 2012-02-03 2021-10-26 Becton, Dickinson And Company External files for distribution of molecular diagnostic tests and determination of compatibility between tests
EP2812339B1 (en) 2012-02-09 2019-11-06 Life Technologies Corporation Hydrophobic diacrylamide compound
KR102019297B1 (en) 2012-02-09 2019-09-06 라이프 테크놀로지스 코포레이션 Hydrophilic polymeric particles and methods for making same
JP6333737B2 (en) 2012-02-09 2018-05-30 ライフ テクノロジーズ コーポレーション Conjugated polymer particles and method for producing the same
EP2814597A4 (en) 2012-02-15 2015-10-28 Bio Rad Laboratories Electronic control of ph and ionic strength
US20150299766A1 (en) 2012-02-23 2015-10-22 Dow Agrosciences Llc Automation of barrier-based plant nucleic acid and protein extraction
ES2619629T3 (en) 2012-03-20 2017-06-26 Aperia Technologies Tire inflation system
US9321012B2 (en) 2012-04-04 2016-04-26 Bio-Rad Laboratories, Inc. Electronic protein fractionation
US10289800B2 (en) 2012-05-21 2019-05-14 Ariosa Diagnostics, Inc. Processes for calculating phased fetal genomic sequences
WO2014018195A1 (en) 2012-06-21 2014-01-30 Monsanto Technology Llc Lysis buffer and methods for extraction of dna from plant material
EP2875156A4 (en) 2012-07-19 2016-02-24 Ariosa Diagnostics Inc Multiplexed sequential ligation-based detection of genetic variants
CN103571824B (en) 2012-08-09 2016-04-13 财团法人工业技术研究院 Compositions and methods for isolating nucleic acids
CN104583397B (en) 2012-08-28 2018-05-25 生物立方体系统有限公司 For being rapidly separated porous solid phase of nucleic acid amplification reaction biomolecule and application thereof from biological sample
GB201216387D0 (en) 2012-09-13 2012-10-31 Ge Healthcare Uk Ltd Solid matrix for one step nucleic acid amplification
US10245908B2 (en) 2016-09-06 2019-04-02 Aperia Technologies, Inc. System for tire inflation
US11453258B2 (en) 2013-03-12 2022-09-27 Aperia Technologies, Inc. System for tire inflation
US10144254B2 (en) 2013-03-12 2018-12-04 Aperia Technologies, Inc. Tire inflation system
US9604157B2 (en) 2013-03-12 2017-03-28 Aperia Technologies, Inc. Pump with water management
US10052428B2 (en) 2013-03-15 2018-08-21 Fenwal, Inc. Methods and systems for the filterless reduction of leukocytes in a biological fluid
SG11201602686YA (en) * 2013-10-07 2016-05-30 Mitsui Chemicals Inc Pcr primer set for bacterial dna amplification, kit for detecting and/or identifying bacterial species, and method for detecting and/or identifying bacterial species
EP3653723B1 (en) 2014-02-10 2022-07-20 Zymo Research Corporation Methods for nucleic acid capture
US20150252407A1 (en) * 2014-03-09 2015-09-10 Nvigen, Inc. Nanostructure and methods of nucleic acid isolation
SG11201609008PA (en) 2014-04-29 2016-11-29 Accudx Corp A novel affinity matrix and devices for isolation and purification of rna and dna for point of care molecular devices
US9879223B2 (en) 2014-07-30 2018-01-30 Fenwal, Inc. Methods and systems for the reduction of leukocytes in a biological fluid
JP6437250B2 (en) * 2014-09-03 2018-12-12 株式会社ミズホメディー Pretreatment method and nucleic acid extraction kit used therefor
WO2016057891A1 (en) 2014-10-09 2016-04-14 Promega Corporation Method of isolating nucleic acid
US10364428B2 (en) 2014-11-14 2019-07-30 Corning Incorporated Methods and kits for post-IVT RNA purification
US11008604B2 (en) * 2014-12-18 2021-05-18 Global Life Sciences Solutions Operations UK Ltd Analyte detection on a solid support by nucleic acid amplification coupled to an immunoassay
GB201504459D0 (en) * 2015-03-17 2015-04-29 Moorlodge Biotech Ventures Ltd Isolation of DNA
US9422596B1 (en) 2015-04-27 2016-08-23 Norgen Biotek Corp. Methods and columns for nucleic acid purification
CN107922974B (en) 2015-07-02 2021-11-09 生命技术公司 Coupling of carboxyl-functional hydrophilic microbeads
US9868826B2 (en) 2015-07-02 2018-01-16 Life Technologies Corporation Polymer substrates formed from carboxy functional acrylamide
US10150992B2 (en) 2015-07-06 2018-12-11 Life Technologies Corporation Substrates and methods useful in sequencing
EP3344643A4 (en) 2015-09-04 2019-05-01 Qiagen Sciences LLC Methods for co-isolation of nucelic acids and proteins
EP3347490A1 (en) * 2015-09-11 2018-07-18 Corning Incorporated Compositions and methods for nucleic acid purification from blood samples
US20180135040A1 (en) 2016-02-16 2018-05-17 Life Magnetics, Inc. Methods for separating nucleic acids with graphene coated magnetic beads
US20190135774A1 (en) * 2016-04-21 2019-05-09 Cell Data Sciences, Inc. Biomolecule processing from fixed biological samples
CA3022947A1 (en) * 2016-05-04 2017-11-09 Children's Hospital & Research Center At Oakland Rapid extraction of nucleic acids from clinical samples for downstream applications
DE102016121483B4 (en) 2016-11-09 2020-06-18 Axagarius Gmbh & Co. Kg Particulate solid composite material for nucleic acid purification, containing magnetic nanoparticles, process for its production and its use
US11129673B2 (en) 2017-05-05 2021-09-28 Uptake Medical Technology Inc. Extra-airway vapor ablation for treating airway constriction in patients with asthma and COPD
JP7323532B2 (en) 2017-09-18 2023-08-08 フェーズ サイエンティフィック インターナショナル リミテッド Methods of Using Aqueous Two-Phase Systems for Isolation, Purification and/or Concentration of Short Nucleic Acid Fragments
US11642920B2 (en) 2018-11-27 2023-05-09 Aperia Technologies, Inc. Hub-integrated inflation system
TWI733302B (en) * 2020-01-09 2021-07-11 創想生物科技有限公司 A method of isolating nucleic acids and the system thereof
KR20220075978A (en) 2020-11-30 2022-06-08 (주)바이오니아 Method of Separating Nucleic Acid by Using Binding Buffer with Chemicals Having Low-Mid Dielectric Constant
CN112626174A (en) * 2020-12-16 2021-04-09 广州源井生物科技有限公司 Cell lysis solution and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5076950A (en) * 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
US5234824A (en) * 1990-11-13 1993-08-10 Specialty Laboratories, Inc. Rapid purification of DNA
US5705628A (en) * 1994-09-20 1998-01-06 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles

Family Cites Families (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US873102A (en) 1907-06-21 1907-12-10 William W Sly Clutch.
SE328534B (en) 1965-08-27 1970-09-21 Astra Ab
US4055469A (en) 1976-12-10 1977-10-25 Eastman Kodak Company Purification of microbial enzyme extracts using synthetic polyelectrolytes
JPS598164B2 (en) 1977-11-30 1984-02-23 三菱重工業株式会社 Tanning equipment for filter materials such as dust masks
AU530410B2 (en) 1978-02-21 1983-07-14 Sintef Preparing aqueous emulsions
JPS5940227B2 (en) 1980-06-24 1984-09-28 富士通株式会社 Reactive sputtering method
EP0046563B1 (en) 1980-08-22 1985-04-10 Laboratorium Prof. Dr. Rudolf Berthold Process for performing analytical determinations by means of the chemiluminescent method, and application of this process to immuno assays
US4379843A (en) 1981-01-26 1983-04-12 Peter Cashion Immobilization of polynucleotides and polypeptides with tritylated polysaccharides
US5055556A (en) 1981-10-06 1991-10-08 The Board Of Trustees Of The Leland Stanford Jr. Univ. Fluorescent conjugates for analysis of molecules and cells
IL65131A0 (en) 1982-02-28 1982-04-30 Yeda Res & Dev Process for the production of agarose-polyaldehyde beads and their biological applications
NO155316C (en) 1982-04-23 1987-03-11 Sintef PROCEDURE FOR MAKING MAGNETIC POLYMER PARTICLES.
US4695537A (en) * 1982-05-21 1987-09-22 The University Of Tennessee Research Corp. Particles sensitized with detergent-treated antigen for agglutination immunoassay
GR79124B (en) 1982-12-22 1984-10-02 Genentech Inc
US4861705A (en) 1983-01-31 1989-08-29 Yeda Research And Development Company, Ltd. Method for removing components of biological fluids
DE3310337A1 (en) 1983-03-22 1984-09-27 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg METHOD FOR CARRYING OUT HYBRIDIZATION REACTIONS
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4648975A (en) 1983-08-17 1987-03-10 Pedro B. Macedo Process of using improved silica-based chromatographic supports containing additives
US4920061A (en) 1984-03-02 1990-04-24 The University Of Texas System Biological magnetic colloids
US4652517A (en) 1984-06-11 1987-03-24 Diagnostic Research Limited Partnership Methods for the in vitro detection and identification of unknown pathogens or genetic entities
AU571979B2 (en) 1984-07-06 1988-04-28 Ciba-Geigy Ag Ionically modified polysaccharides
GB8501671D0 (en) 1985-01-23 1985-02-27 Allen G J Immunoassay
GB8507706D0 (en) 1985-03-25 1985-05-01 Genetics Int Inc Magnetic nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4897444A (en) 1985-05-31 1990-01-30 The Research Foundation Of The State University Of New York Immobilized fluorogenic substrates for enzymes; and processes for their preparation
US4710472A (en) 1985-09-25 1987-12-01 The United States Of America As Represented By The Secretary Of The Navy Magnetic separation device
US4889916A (en) 1985-11-19 1989-12-26 The Johns Hopkins University Protein label and drug delivery system
US4772550A (en) 1986-02-10 1988-09-20 Miles Inc. Heterogeneous specific binding assay employing an aggregatable binding reagent
US4871433A (en) 1986-04-04 1989-10-03 Materials Research Corporation Method and apparatus for improving the uniformity ion bombardment in a magnetron sputtering system
US6881536B1 (en) 1986-04-30 2005-04-19 Bioveris Corporation Particle based electrochemiluminescent assays
FR2600655B1 (en) 1986-06-30 1988-10-21 Centre Nat Rech Scient PROTEIN FRACTION EXTRACTED FROM GROWTH FACTOR ACTIVITIES, OBTAINING AND APPLICATION AS A STIMULATION AND POTENTIALIZING AGENT FOR GROWTH FACTOR ACTIVITIES
US4843012A (en) 1986-09-17 1989-06-27 Genetics Institute, Inc. Novel composition for nucleic acid purification
DE3639949A1 (en) 1986-11-22 1988-06-09 Diagen Inst Molekularbio METHOD FOR SEPARATING LONG CHAIN NUCLEIC ACIDS
US4935342A (en) 1986-12-01 1990-06-19 Syngene, Inc. Method of isolating and purifying nucleic acids from biological samples
US4767670A (en) 1987-01-21 1988-08-30 E. I. Du Pont De Nemours And Company Chromatographic supports for separation of oligonucleotides
US4874813A (en) 1987-02-09 1989-10-17 Shannessy Daniel J O Proteins bound to a marker or solid phase support matrix using a hydrazone linkage
NO162946C (en) 1987-08-21 1990-03-14 Otto Soerensen DEVICE FOR MAGNETIC SEPARATION OF CELLS.
WO1988006633A1 (en) 1987-03-02 1988-09-07 Arnold Lyle John Jr Polycationic supports for nucleic acid purification, separation and hybridization
US5079155A (en) 1987-03-02 1992-01-07 E. I. Du Pont De Nemours And Company Fluorocarbon polymer support for chromatographic separations, diagnostic assays and enzyme immobilization
US5599667A (en) 1987-03-02 1997-02-04 Gen-Probe Incorporated Polycationic supports and nucleic acid purification separation and hybridization
DE3717211A1 (en) 1987-05-22 1988-12-01 Diagen Inst Molekularbio DEVICE AND METHOD FOR SEPARATING AND CLEANING MOLECULES
US4921805A (en) 1987-07-29 1990-05-01 Life Technologies, Inc. Nucleic acid capture method
JPH01125395A (en) 1987-07-29 1989-05-17 Life Technol Inc Nuclic acid catching reagent
FR2619568B1 (en) 1987-08-21 1989-07-07 Centre Nat Rech Scient POLYSTYRENE-DERIVED POLYMERS, PROCESSES FOR THE PREPARATION THEREOF AND APPLICATIONS THEREOF FOR THE ANALYSIS AND PURIFICATION OF ORGANIC MOLECULES
US4908318A (en) 1987-09-04 1990-03-13 Integrated Genetics, Inc. Nucleic acid extraction methods
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US4923978A (en) 1987-12-28 1990-05-08 E. I. Du Pont De Nemours & Company Process for purifying nucleic acids
GB8800702D0 (en) 1988-01-13 1988-02-10 Nycomed As Test method & reagent kit therefor
US5183809A (en) 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US4875045A (en) 1988-03-09 1989-10-17 Northern Telecom Limited Variable gain encoder apparatus and method
EP0338591A3 (en) 1988-04-21 1991-09-04 Microprobe Corporation Nucleic acid extraction method
US4952519A (en) 1988-05-02 1990-08-28 E. I. Du Pont De Nemours And Company Protein immobilization with poly(ethyleneimine) derivatized with a hydroprobic group
DE3921498A1 (en) 1988-09-28 1990-03-29 Bayer Ag POLYMER-TIED DYES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5807527A (en) 1991-05-29 1998-09-15 Flinders Technologies Pty. Ltd. Solid medium and method for DNA storage
CA1335181C (en) 1988-10-11 1995-04-11 R. Alan Hardwick System for selective cell separation from cell concentrate
IE883226L (en) 1988-10-25 1990-04-25 Dna Prep Galway Ltd S 22 Separation of nucleic acids from protein material using¹cation exchangers
US5028696A (en) 1988-10-28 1991-07-02 Torres Anthony R Ion exchange and separation method
US6448091B1 (en) 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
GB8827160D0 (en) 1988-11-21 1988-12-29 Apothekernes Lab Detection & quantitative determination of rna & dna
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
CA2005927A1 (en) 1988-12-21 1990-06-21 Chander Bahl Method of preparing nucleotide probes using a bridging complement
WO1990008159A1 (en) 1989-01-23 1990-07-26 Invitron Corporation Method for removing dna from protein preparations
NL8900725A (en) 1989-03-23 1990-10-16 Az Univ Amsterdam METHOD AND COMBINATION OF AGENTS FOR INSULATING NUCLEIC ACID.
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
JP2910929B2 (en) 1989-03-23 1999-06-23 浜松ホトニクス株式会社 Surface modification method for particles composed of magnetic particles
US5126028A (en) 1989-04-17 1992-06-30 Materials Research Corporation Sputter coating process control method and apparatus
US4957605A (en) 1989-04-17 1990-09-18 Materials Research Corporation Method and apparatus for sputter coating stepped wafers
US5334499A (en) 1989-04-17 1994-08-02 Eastman Kodak Company Methods of extracting, amplifying and detecting a nucleic acid from whole blood or PBMC fraction
US6010867A (en) 1989-04-19 2000-01-04 Ibiden Co., Ltd. Reagent for biomaterials assay, preparation method thereof, and assay method
DE3916595A1 (en) 1989-05-22 1990-11-29 Boehringer Mannheim Gmbh METHOD FOR NON-RADIOACTIVE MEASURING OF NUCLEIC ACID SYNTHESIS IN EUKARYONTIC CELLS
NO168811C (en) 1989-05-31 1992-04-08 Dynal As Separation device for separating magnetizable particles
US5124444A (en) 1989-07-24 1992-06-23 Microprobe Corporation Lactam-containing compositions and methods useful for the extraction of nucleic acids
EP0416748B1 (en) 1989-08-07 1994-03-30 J.T. Baker Inc. Quaternised pei silica solid supports for chromatography
US5032281A (en) 1989-08-09 1991-07-16 Daicel Chemical Industries, Ltd. Separating membrane and separation method
US5128247A (en) 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5084169A (en) 1989-09-19 1992-01-28 The University Of Colorado Foundation, Inc. Stationary magnetically stabilized fluidized bed for protein separation and purification
US5433847A (en) 1989-11-01 1995-07-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Radial flow chromatography
US4997932A (en) 1989-11-13 1991-03-05 Boehringer Mannheim Corporation Method and kit for purifying nucleic acids
WO1991007660A1 (en) 1989-11-13 1991-05-30 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal dna
US5641628A (en) 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
US5000635A (en) 1989-11-17 1991-03-19 The Boeing Company Spring-loaded outboard side lock
DE69029740T2 (en) 1989-11-30 1997-07-10 Pharmacia Biotech Ab NEW METHOD FOR DETECTING A SPECIFIC NUCLEIC ACID SEQUENCE IN A CELL SAMPLE
GB9003253D0 (en) 1990-02-13 1990-04-11 Amersham Int Plc Precipitating polymers
US5523231A (en) 1990-02-13 1996-06-04 Amersham International Plc Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules
IT1240870B (en) 1990-02-14 1993-12-17 Talent PROCEDURE FOR THE EXTRACTION AND PURIFICATION OF HUMAN GENOMIC DNA
CA2082936C (en) 1990-05-15 2003-09-23 Peter O. G. Arrhenius Fluorescent porphyrin, and fluorescent phthalocyanine-polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes
US5234924A (en) 1990-09-26 1993-08-10 Adir Et Compagnie Benzothiazine and benzothiazole compounds useful as analgesics
DE4034036C2 (en) 1990-10-26 1994-03-03 Diagen Inst Molekularbio Device and method for isolating nucleic acids from cell suspensions
JPH06510363A (en) 1990-10-29 1994-11-17 ディカルブ プラント ジェネティクス Isolation of biological materials using magnetic particles
US5654179A (en) 1990-11-14 1997-08-05 Hri Research, Inc. Nucleic acid preparation methods
DE4038293A1 (en) 1990-11-28 1992-06-04 Inst Molekularbiologie Ak Nucleic acid adduct for in situ hybridisation to give nucleic acid sequences - comprises water soluble basic polymer and nucleic acid sequence formed by polymerase chain reaction and/or reverse transcriptase reaction
US5204246A (en) 1990-12-26 1993-04-20 Pioneer Hi-Bred International, Inc. Dna isolation method
US5296347A (en) 1991-02-08 1994-03-22 Ciba Corning Diagnostics Corp. Bridge immunoassay
US5491223A (en) 1991-02-28 1996-02-13 Daicel Chemical Industries, Ltd. Polysaccharide derivative and separating agent
GB9107124D0 (en) 1991-04-05 1991-05-22 Dynal As Chemical process
CA2067711C (en) 1991-05-03 2000-08-08 Daniel Lee Woodard Solid phase extraction purification of dna
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5155018A (en) 1991-07-10 1992-10-13 Hahnemann University Process and kit for isolating and purifying RNA from biological sources
FR2679255B1 (en) 1991-07-17 1993-10-22 Bio Merieux METHOD OF IMMOBILIZING A NUCLEIC FRAGMENT BY PASSIVE FIXING ON A SOLID SUPPORT, SOLID SUPPORT THUS OBTAINED AND ITS USE.
JPH07504801A (en) 1991-08-06 1995-06-01 ザ ワールド ヘルス オーガニゼイション DNA isolation method
US5329000A (en) 1991-10-31 1994-07-12 Becton, Dickinson And Company Purification of DNA with silicon tetrahydrazide
US6051380A (en) 1993-11-01 2000-04-18 Nanogen, Inc. Methods and procedures for molecular biological analysis and diagnostics
EP0555798B1 (en) 1992-02-13 1999-05-06 Becton, Dickinson and Company Hydrated celite and purification of DNA
DE4208645A1 (en) 1992-03-18 1993-09-23 Bayer Ag OPTICAL SOLID PHASE BIOSENSOR BASED ON FLUORESCENT COLOR-MARGINED POLYIONIC LAYERS
DE4237381C1 (en) 1992-11-05 1994-04-28 Diagen Inst Molekularbio Carrier material for the simultaneous binding of genotypic and phenotypic substances
GB9212164D0 (en) * 1992-06-09 1992-07-22 Medical Res Council Preparation of nucleic acids
US5710028A (en) 1992-07-02 1998-01-20 Eyal; Nurit Method of quick screening and identification of specific DNA sequences by single nucleotide primer extension and kits therefor
GB9220773D0 (en) 1992-10-02 1992-11-18 Mini Agriculture & Fisheries Detection of antigens and nucleic acids
GB2272391A (en) 1992-11-05 1994-05-18 Gordon Henry Turner Drilling jig
GB9223334D0 (en) 1992-11-06 1992-12-23 Hybaid Ltd Magnetic solid phase supports
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DE69428891T2 (en) 1993-03-29 2002-06-27 Minnesota Mining & Mfg METHOD FOR CONNECTING LIGANDS IN A POROUS CARRIER (e.g. AZLAKTON) AND ITS APPLICATIONS
US5438129A (en) 1993-09-27 1995-08-01 Becton Dickinson And Company DNA purification by solid phase extraction using partially fluorinated aluminum hydroxide adsorbant
US5503816A (en) 1993-09-27 1996-04-02 Becton Dickinson And Company Silicate compounds for DNA purification
GB2282138B (en) 1993-09-28 1997-09-03 Tosoh Corp Method of extracting nucleic acids and method of detecting specified nucleic acid sequences
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US20030044777A1 (en) 1993-10-28 2003-03-06 Kenneth L. Beattie Flowthrough devices for multiple discrete binding reactions
GB9323305D0 (en) 1993-11-11 1994-01-05 Medinnova Sf Isoaltion of nucleic acid
DE4432654C2 (en) 1994-09-14 1998-03-26 Qiagen Gmbh Process for the isolation of nucleic acids from natural sources
WO1995027718A2 (en) 1994-04-08 1995-10-19 Hybridon, Inc. Purification of oligodeoxynucleotide phosphorothioates using anion exchange chromatography
AU2907995A (en) 1994-06-23 1996-01-19 Dade International Inc. Method for the rapid isolation of nucleic acid
KR100208546B1 (en) 1994-08-25 1999-07-15 야마오까 유지 Vertical hole excavating machine
US5622822A (en) 1994-09-13 1997-04-22 Johnson & Johnson Clinical Diagnostics, Inc. Methods for capture and selective release of nucleic acids using polyethyleneimine and an anionic phosphate ester surfactant and amplification of same
US5582988A (en) 1994-09-15 1996-12-10 Johnson & Johnson Clinical Diagnostics, Inc. Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same
US5652348A (en) 1994-09-23 1997-07-29 Massey University Chromatographic resins and methods for using same
US5660984A (en) 1994-12-09 1997-08-26 Davis; Thomas E. DNA isolating apparatus comprising a non-porous DNA binding, anion exchange resin and methods of use thereof
GB9425138D0 (en) 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5762903A (en) 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
KR100380875B1 (en) 1995-04-28 2003-10-10 다이이찌 세이야꾸 가부시기가이샤 Pentacyclic compound
US5702147A (en) * 1995-05-09 1997-12-30 Bestop, Inc. Tailgate sealing arrangement
AR003122A1 (en) 1995-05-19 1998-07-08 Merck & Co Inc A PROCESS FOR ISOLATION AND PURIFICATION OF PLASMIDS IN LARGE SCALE FERMENTATORS AND ISOLATED AND PURIFIED DNA OBTAINED THROUGH SUCH A PROCESS.
KR19990022612A (en) 1995-06-08 1999-03-25 퍼니스 챨스 엠 DNA Extraction Method and Extraction Apparatus
DE19520398B4 (en) 1995-06-08 2009-04-16 Roche Diagnostics Gmbh Magnetic pigment
JP2965131B2 (en) 1995-07-07 1999-10-18 東洋紡績株式会社 Magnetic carrier for nucleic acid binding and nucleic acid isolation method using the same
ATE200236T1 (en) 1995-08-28 2001-04-15 Advanced Nano Technologies Pty METHOD FOR PRODUCING ULTRA FINE PARTICLES
US5783686A (en) 1995-09-15 1998-07-21 Beckman Instruments, Inc. Method for purifying nucleic acids from heterogenous mixtures
JP3372551B2 (en) 1995-11-21 2003-02-04 ノバルティス アクチエンゲゼルシャフト Polyvalent polymers, methods for their preparation and their use in the preparation of biologically active compounds
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
US6803188B1 (en) 1996-01-31 2004-10-12 The Regents Of The University Of California Tandem fluorescent protein constructs
US5981735A (en) 1996-02-12 1999-11-09 Cobra Therapeutics Limited Method of plasmid DNA production and purification
SE9600590D0 (en) 1996-02-19 1996-02-19 Pharmacia Biotech Ab Methods for chromatographic separation of peptides and nucleic acid and new high-affinity ion exchange matrix
DE69738791D1 (en) 1996-02-25 2008-08-07 Prec System Science Co Ltd METHOD FOR THE TREATMENT OF BIOPOLYMERS, MICRO-ORGANISMS OR OTHER MATERIALS USING MORE THAN ONE TYPE OF MAGNETIC PARTICLES.
NO961221D0 (en) 1996-03-26 1996-03-26 Oeystein Fodstad Method of identifying new genes associated with site-preferential cancer metastasis formation
SE9601318D0 (en) 1996-04-04 1996-04-04 Pharmacia Biosensor Ab Method for nucleic acid analysis
US5780319A (en) 1996-04-19 1998-07-14 Pasteur Sanofi Diagnostics Immunoassays to detect antiphospholipid antibodies
US5916746A (en) 1996-05-09 1999-06-29 Kirkegaard & Perry Laboratories, Inc. Formazan-based immunoassay
US5962412A (en) 1996-06-10 1999-10-05 Arqule, Inc. Method of making polymers having specific properties
US5981235A (en) 1996-07-29 1999-11-09 Promega Corporation Methods for isolating nucleic acids using alkaline protease
JP3793287B2 (en) 1996-08-22 2006-07-05 ペンタックス株式会社 Method for isolating plasmid DNA
CA2214495C (en) 1996-09-25 2002-02-05 Daniel L. Woodard Hydrated zirconium silicate composition for purification of nucleic acids
US5795748A (en) 1996-09-26 1998-08-18 Becton Dickinson And Company DNA microwell device and method
AU724492B2 (en) 1996-10-10 2000-09-21 Biotechnology Research And Development Corporation Polymer-protein composites and methods for their preparation and use
CA2268740C (en) 1996-11-06 2010-07-20 Sequenom, Inc. High density immobilization of nucleic acids
US6060246A (en) 1996-11-15 2000-05-09 Avi Biopharma, Inc. Reagent and method for isolation and detection of selected nucleic acid sequences
EP0853123A1 (en) 1997-01-10 1998-07-15 Roche Diagnostics GmbH Purification of DNA by 'cross-flow-filtration'
US6027945A (en) 1997-01-21 2000-02-22 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
US5770712A (en) 1997-03-14 1998-06-23 Virginia Tech Intellectual Properties, Inc. Crosslinked hydrogel beads from chitosan
GB9709728D0 (en) * 1997-05-13 1997-07-02 Dynal As Single step method
US20040152084A1 (en) 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
US5958788A (en) 1997-05-28 1999-09-28 Nalco Chemical Company Luminol tagged polymers for treatment of industrial systems
CA2293820A1 (en) 1997-06-25 1998-12-30 Promega Corporation Method of isolating rna
EP0897978A3 (en) 1997-08-22 2001-10-17 Becton, Dickinson and Company Zirconium oxide and related compounds for purification of nucleic acids
DE19739218A1 (en) 1997-09-08 1999-03-11 Boehringer Mannheim Gmbh Purification of substances from a biological sample
JP4304348B2 (en) 1997-09-22 2009-07-29 独立行政法人理化学研究所 DNA isolation method
DE19746874A1 (en) 1997-10-23 1999-04-29 Qiagen Gmbh Isolation of nucleic acids
CA2305995A1 (en) 1997-10-23 1999-05-06 Nicholas A.D. Burke Labelling of polymers and sequencing of nucleic acids
DE19747572C1 (en) 1997-10-28 1999-04-08 Inst Chemo Biosensorik Apparatus for fluorescence immunoassay
US6120985A (en) 1997-10-31 2000-09-19 Bbi Bioseq, Inc. Pressure-enhanced extraction and purification
GB9725197D0 (en) 1997-11-29 1998-01-28 Secr Defence Detection system
US6914137B2 (en) 1997-12-06 2005-07-05 Dna Research Innovations Limited Isolation of nucleic acids
ATE218140T1 (en) 1997-12-06 2002-06-15 Dna Res Innovations Ltd ISOLATION OF NUCLEIC ACIDS
EP1062515B1 (en) 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
FR2777355B1 (en) 1998-04-10 2000-05-12 Bio Merieux PROCESS FOR FIXING A BIOLOGICAL MOLECULE ON THE SURFACE OF A SUPPORT CONSISTING OF SILICA OR METAL OXIDE
US6194562B1 (en) 1998-04-22 2001-02-27 Promega Corporation Endotoxin reduction in nucleic acid purification
US7078224B1 (en) 1999-05-14 2006-07-18 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US6287772B1 (en) 1998-04-29 2001-09-11 Boston Probes, Inc. Methods, kits and compositions for detecting and quantitating target sequences
US6534262B1 (en) 1998-05-14 2003-03-18 Whitehead Institute For Biomedical Research Solid phase technique for selectively isolating nucleic acids
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6245507B1 (en) 1998-08-18 2001-06-12 Orchid Biosciences, Inc. In-line complete hyperspectral fluorescent imaging of nucleic acid molecules
AU2025400A (en) 1998-11-17 2000-06-05 Proteo Tools Separation, screening, and identification of biological targets
ATE317297T1 (en) 1998-11-23 2006-02-15 Us Gov Sec Army CLEANING METHOD AND APPARATUS
FI990082A0 (en) 1999-01-18 1999-01-18 Labsystems Oy Purification process using magnetic particles
EP1147226B1 (en) 1999-01-27 2013-01-23 Folim G. Halaka Materials and methods for the purification of polyelectrolytes
CA2360042A1 (en) 1999-01-29 2000-08-03 Amersham Pharmacia Biotech K.K. Temperature-responsive polymer compound and process for producing the same
DE19907023A1 (en) 1999-02-19 2000-08-24 Bayer Ag Isolation of nucleic acids, useful for e.g. genetic diagnosis by amplification, by adsorption onto polymeric beads at neutral or acidic pH then release at basic pH
GB9907245D0 (en) 1999-03-29 1999-05-26 Goldsborough Andrew Cleavage of nucleic acids from solid supports
AU4058100A (en) 1999-04-09 2000-11-14 Arcturus Engineering, Inc. Generic cdna or protein array for customized assays
CA2270106C (en) 1999-04-23 2006-03-14 Yousef Haj-Ahmad Nucleic acid purification and process
US6270970B1 (en) 1999-05-14 2001-08-07 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
US6310199B1 (en) 1999-05-14 2001-10-30 Promega Corporation pH dependent ion exchange matrix and method of use in the isolation of nucleic acids
JP4551568B2 (en) 1999-05-14 2010-09-29 プロメガ コーポレイション Cell collection and lysate clarification using paramagnetic particles
US6472141B2 (en) 1999-05-21 2002-10-29 Caliper Technologies Corp. Kinase assays using polycations
US6645733B1 (en) 1999-06-25 2003-11-11 Ingeneus Corporation Fluorescent intensity method for assaying binding between proteins or peptides
ATE320443T1 (en) 1999-07-15 2006-04-15 Qiagen Gmbh METHOD FOR SEPARATING PARTICLE SUBSTRATES FROM A SOLUTION BY MINIMIZING PARTICLE LOSS
WO2001038585A2 (en) 1999-11-24 2001-05-31 The Regents Of The University Of California Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression
US6582907B1 (en) 1999-12-09 2003-06-24 Pharmacia & Upjohn Company Use of fluorescence correlation spectroscopy to identify compounds that bind to target species under isothermal denaturing conditions
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
US6489160B2 (en) 2000-03-16 2002-12-03 Kabushiki Kaisha Toshiba Method for producing nucleic acid strand immobilized carrier
US7262006B1 (en) 2000-05-01 2007-08-28 Ortho-Clinical Diagnostics, Inc. Rapid and efficient capture of DNA from sample without using cell lysing reagent
GB0013658D0 (en) 2000-06-05 2000-07-26 Dynal Asa Nucleic acid isolation
US7501284B2 (en) 2000-07-31 2009-03-10 Applera Corporation Apparatus and method for specific release of captured extension products
AU2001281000A1 (en) 2000-08-24 2002-03-04 Bio-Rad Laboratories, Inc. Flow-through system for lysate clarification and nucleic acid binding in a single step
US6627748B1 (en) 2000-09-11 2003-09-30 The Trustees Of Columbia University In The City Of New York Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses
GB0026560D0 (en) 2000-10-30 2000-12-13 Novartis Ag Organic compounds
DE60015360T9 (en) 2000-11-20 2005-12-15 Sony International (Europe) Gmbh Method for the immobilization of nucleic acids on a solid support
US6743586B2 (en) 2001-01-29 2004-06-01 The United States Of America As Represented By The Secretary Of The Commerce Rapid fluorescence detection of binding to nucleic acid drug targets labelled with highly fluorescent nucleotide base analogs
JP3975319B2 (en) 2001-03-02 2007-09-12 富士ゼロックス株式会社 Developing device and image forming apparatus using the same
US7018610B2 (en) 2001-03-02 2006-03-28 University Of Western Ontario Polymer precursors of radiolabeled compounds, and methods of making and using the same
AU2002258997A1 (en) 2001-04-24 2002-11-05 Li-Cor, Inc. Polymerases with charge-switch activity and methods of generating such polymerases
US7338805B2 (en) 2001-05-04 2008-03-04 Bio Merieux Labeling reagents, methods for synthesizing such reagents and methods for detecting biological molecules
US7183116B2 (en) 2001-05-14 2007-02-27 The Institute For Systems Biology Methods for isolation and labeling of sample molecules
WO2003017938A2 (en) 2001-08-22 2003-03-06 Watson Pharmaceuticals, Inc. Conjugates targeted to target receptors
US20030099954A1 (en) 2001-11-26 2003-05-29 Stefan Miltenyi Apparatus and method for modification of magnetically immobilized biomolecules
US20030229013A1 (en) 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
US7056682B2 (en) 2001-12-27 2006-06-06 Matsushita Electric Industrial Co., Ltd. Immunoassay method and immunoassay reagent kit to be used therein
US20030147958A1 (en) 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
AU2003222117A1 (en) 2002-03-29 2003-10-13 Genentech, Inc. Methods and compositions for detection and quantitation of nucleic acid analytes
GB0209539D0 (en) 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
GB0212826D0 (en) 2002-05-31 2002-07-10 Dna Res Innovations Ltd Materials and methods relating to polyions and substance delivery
CA2489922C (en) 2002-06-20 2016-08-16 The Regents Of The University Of California Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores
EP1411122B1 (en) 2002-10-18 2008-07-09 Sloning BioTechnology GmbH Method for the manufacture of nucleic acid molecules
FR2847581B1 (en) 2002-11-21 2007-03-23 Commissariat Energie Atomique METHOD FOR FIXING A PROTEIN ON A POLYMER BASED ON PYRROLE AND ITS USE IN THE MANUFACTURE OF A SENSOR
GB0229287D0 (en) 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
US20050123932A1 (en) 2003-12-09 2005-06-09 Mekbib Astatke Nucleic acid-chelating agent conjugates
BE1016163A6 (en) 2004-08-18 2006-04-04 Mc Anton Sa METHOD Percutaneous HYPERBARIC OXYGEN SPRAY fluorocarbons.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5076950A (en) * 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
US5234824A (en) * 1990-11-13 1993-08-10 Specialty Laboratories, Inc. Rapid purification of DNA
US5705628A (en) * 1994-09-20 1998-01-06 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989614B2 (en) 1994-12-12 2011-08-02 Invitrogen Dynal As Isolation of nucleic acid
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US8110351B2 (en) 2002-01-16 2012-02-07 Invitrogen Dynal As Method for isolating nucleic acids and protein from a single sample
WO2009040444A1 (en) * 2007-09-28 2009-04-02 Mole Genetics As Rna isolation method
GB2466419A (en) * 2007-09-28 2010-06-23 Mole Genetics As RNA isolation method
GB2466419B (en) * 2007-09-28 2011-04-13 Mole Genetics As RNA isolation method
US20110104157A1 (en) * 2008-04-04 2011-05-05 Chugai Seiyaku Kabushiki Kaisha Liver cancer drug

Also Published As

Publication number Publication date
WO1996018731A3 (en) 1996-09-12
US20090068724A1 (en) 2009-03-12
AU4182996A (en) 1996-07-03
DE69533317D1 (en) 2004-09-02
US20110251382A1 (en) 2011-10-13
ATE272110T1 (en) 2004-08-15
DE69533317T2 (en) 2005-12-01
US20060058519A1 (en) 2006-03-16
US8691969B2 (en) 2014-04-08
EP0796327B1 (en) 2004-07-28
US20140291576A1 (en) 2014-10-02
US7173124B2 (en) 2007-02-06
CA2207608C (en) 2009-04-07
US20090149646A1 (en) 2009-06-11
AU706211B2 (en) 1999-06-10
EP0796327A2 (en) 1997-09-24
JPH11501504A (en) 1999-02-09
GB9425138D0 (en) 1995-02-08
JP3787354B2 (en) 2006-06-21
US7989614B2 (en) 2011-08-02
US20080300396A1 (en) 2008-12-04
US20040215011A1 (en) 2004-10-28
CA2207608A1 (en) 1996-06-20
WO1996018731A2 (en) 1996-06-20

Similar Documents

Publication Publication Date Title
US7989614B2 (en) Isolation of nucleic acid
US9464316B2 (en) Method for isolating nucleic acids comprising the use of ethylene glycol multimers
AU751324C (en) Solid-phase nucleic acid isolation
US8202693B2 (en) Method of isolation of nucleic acids
US20070031880A1 (en) Chemical treatment of biological samples for nucleic acid extraction and kits therefor

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: INVITROGEN DYNAL AS, NORWAY

Free format text: CHANGE OF NAME;ASSIGNORS:DNYAL AS;DYNAL ASA;DYNAL BIOTECH ASA;AND OTHERS;SIGNING DATES FROM 19990922 TO 20060322;REEL/FRAME:026978/0392